# Quinn_2021_Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the detection of dementia within community dwelling populations.

Cochrane
Library

Cochrane Database of Systematic Reviews

Informant Questionnaire on Cognitive Decline in the Elderly
(IQCODE) for the detection of dementia within community dwelling
populations (Review)

Quinn TJ, Fearon P, Noel-Storr AH, Young C, McShane R, Stott DJ

Quinn TJ, Fearon P, Noel-Storr AH, Young C, McShane R, Stott DJ. 
Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the detection of dementia within community dwelling
populations. 
Cochrane Database of Systematic Reviews 2021, Issue 7. Art. No.: CD010079. 
DOI: 10.1002/14651858.CD010079.pub3.

www.cochranelibrary.com

Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the detection of dementia within
community dwelling populations (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

T A B L E   O F   C O N T E N T S

ABSTRACT.....................................................................................................................................................................................................
PLAIN LANGUAGE SUMMARY.......................................................................................................................................................................
SUMMARY OF FINDINGS..............................................................................................................................................................................
BACKGROUND..............................................................................................................................................................................................
OBJECTIVES..................................................................................................................................................................................................
METHODS.....................................................................................................................................................................................................
RESULTS........................................................................................................................................................................................................
Figure 1..................................................................................................................................................................................................
Figure 2..................................................................................................................................................................................................
Figure 3..................................................................................................................................................................................................
Figure 4..................................................................................................................................................................................................
Figure 5..................................................................................................................................................................................................
Figure 6..................................................................................................................................................................................................
Figure 7..................................................................................................................................................................................................
DISCUSSION..................................................................................................................................................................................................
AUTHORS' CONCLUSIONS...........................................................................................................................................................................
ACKNOWLEDGEMENTS................................................................................................................................................................................
REFERENCES................................................................................................................................................................................................
CHARACTERISTICS OF STUDIES..................................................................................................................................................................
DATA..............................................................................................................................................................................................................
Test 3. accuracy of IQCODE at 3.3 threshold or nearest (16 and 26 item included)..........................................................................
Test 4. accuracy of IQCODE at 3.3 threshold (16 and 26 item IQCODE included)..............................................................................
Test 5. accuracy of IQCODE at 3.4 threshold (16 and 26 item IQCODE included)..............................................................................
Test 6. accuracy of IQCODE at 3.5 threshold (16 and 26 item IQCODE included)..............................................................................
Test 7. accuracy of IQCODE at 3.6 threshold (16 and 26 item IQCODE included)..............................................................................
Test 8. 16 item IQCODE 3.3 threshold..................................................................................................................................................
Test 9. 16 item IQCODE 3.4 threshold..................................................................................................................................................
Test 10. 16 item IQCODE 3.5 threshold................................................................................................................................................
Test 11. 16 item IQCODE 3.6 threshold................................................................................................................................................
Test 12. 26 item IQCODE 3.3 threshold................................................................................................................................................
Test 13. 26 item IQCODE 3.4 threshold................................................................................................................................................
Test 14. 26 item IQCODE 3.5 threshold................................................................................................................................................
Test 15. 26 item IQCODE 3.6 threshold................................................................................................................................................
Test 16. all IQCODE studies at 3.3 threshold with Srikanth removed................................................................................................
Test 17. all IQCODE studies at 3.4 threshold with Senanorong removed..........................................................................................
Test 18. all IQCODE studies at 3.5 threshold with Senanorong removed..........................................................................................
ADDITIONAL TABLES....................................................................................................................................................................................
APPENDICES.................................................................................................................................................................................................
WHAT'S NEW.................................................................................................................................................................................................
HISTORY........................................................................................................................................................................................................
CONTRIBUTIONS OF AUTHORS...................................................................................................................................................................
DECLARATIONS OF INTEREST.....................................................................................................................................................................
SOURCES OF SUPPORT...............................................................................................................................................................................
DIFFERENCES BETWEEN PROTOCOL AND REVIEW....................................................................................................................................
INDEX TERMS...............................................................................................................................................................................................

Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the detection of dementia within community dwelling
populations (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

1
2
3
8
10
10
13
14
15
16
18
20
21
22
23
25
25
27
32
51
52
53
53
53
53
53
54
54
54
54
54
54
55
55
55
55
55
56
79
80
80
80
80
80
80

i

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

[Diagnostic Test Accuracy Review]

Cochrane Database of Systematic Reviews

Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE)
for the detection of dementia within community dwelling populations

Terry J Quinn1, Patricia Fearon2, Anna H Noel-Storr3, Camilla Young1, Rupert McShane4, David J Stott5

1Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK. 2Academic Section of Geriatric Medicine,
University of Glasgow, Glasgow, UK. 3Radcliffe Department of Medicine, University of Oxford , Oxford, UK. 4Oxford Health NHS
Foundation Trust, Oxford, UK. 5Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow , UK

Contact: Terry J Quinn, Terry.Quinn@glasgow.ac.uk.

Editorial group: Cochrane Dementia and Cognitive Improvement Group.
Publication status and date: Edited (no change to conclusions), published in Issue 7, 2021.

Citation: Quinn TJ, Fearon P, Noel-Storr AH, Young C, McShane R, Stott DJ. Informant Questionnaire on Cognitive Decline in the Elderly
(IQCODE) for the detection of dementia within community dwelling populations. Cochrane Database of Systematic Reviews 2021, Issue 7.
Art. No.: CD010079. DOI: 10.1002/14651858.CD010079.pub3.

Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Background

A B S T R A C T

Various tools exist for initial assessment of possible dementia with no consensus on the optimal assessment method. Instruments that
use collateral sources to assess change in cognitive function over time may have particular utility. The most commonly used informant
dementia assessment is the Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE).

A synthesis of the available data regarding IQCODE accuracy will help inform cognitive assessment strategies for clinical practice, research
and policy.

Objectives

Our  primary  obective  was  to  determine  the  accuracy  of  the  informant-based  questionnaire  IQCODE  for  detection  of  dementia  within
community dwelling populations.

Our secondary objective was to describe the effect of heterogeneity on the summary estimates. We were particularly interested in the
traditional 26-item scale versus the 16-item short form; and language of administration. We explored the effect of varying the threshold
IQCODE score used to define 'test positivity'.

Search methods

We searched the following sources on 28 January 2013: ALOIS (Cochrane Dementia and Cognitive Improvement Group), MEDLINE (OvidSP),
EMBASE (OvidSP), PsycINFO (OvidSP), BIOSIS Previews (ISI Web of Knowledge), Web of Science with Conference Proceedings (ISI Web of
Knowledge), LILACS (BIREME). We also searched sources relevant or specific to diagnostic test accuracy: MEDION (Universities of Maastrict
and  Leuven);  DARE  (York  University);  ARIF  (Birmingham  University).  We  used  sensitive  search  terms  based  on  MeSH  terms  and  other
controlled vocabulary.

Selection criteria

We selected those studies performed in community settings that used (not necessarily exclusively) the IQCODE to assess for presence of
dementia and, where dementia diagnosis was confirmed with clinical assessment. Our intention with limiting the search to a 'community'
setting was to include those studies closest to population level assessment. Within our predefined community inclusion criteria, there were
relevant papers that fulfilled our definition of community dwelling but represented a selected population, for example stroke survivors. We
included these studies but performed sensitivity analyses to assess the effects of these less representative populations on the summary
results.

Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the detection of dementia within community dwelling
populations (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

1

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Data collection and analysis

Cochrane Database of Systematic Reviews

We screened all titles generated by the electronic database searches and abstracts of all potentially relevant studies were reviewed. Full
papers were assessed for eligibility and data extracted by two independent assessors. For quality assessment (risk of bias and applicability)
we used the QUADAS 2 tool. We included test accuracy data on the IQCODE used at predefined diagnostic thresholds. Where data allowed,
we performed meta-analyses to calculate summary values of sensitivity and specificity with corresponding 95% confidence intervals (CIs).
We  pre-specified  analyses  to  describe  the  effect  of  IQCODE  format  (traditional  or  short  form)  and  language  of  administration  for  the
IQCODE.

Main results

From 16,144 citations, 71 papers described IQCODE test accuracy. We included 10 papers (11 independent datasets) representing data
from 2644 individuals (n = 379 (14%) with dementia). Using IQCODE cut-offs commonly employed in clinical practice (3.3, 3.4, 3.5, 3.6) the
sensitivity and specificity of IQCODE for diagnosis of dementia across the studies were generally above 75%.

Taking an IQCODE threshold of 3.3 (or closest available) the sensitivity was 0.80 (95% CI 0.75 to 0.85); specificity was 0.84 (95% CI 0.78 to
0.90); positive likelihood ratio was 5.2 (95% CI 3.7 to 7.5) and the negative likelihood ratio was 0.23 (95% CI 0.19 to 0.29).

Comparative  analysis  suggested  no  significant  difference  in  the  test  accuracy  of  the  16  and  26-item  IQCODE  tests  and  no  significant
difference in test accuracy by language of administration. There was little difference in sensitivity across our predefined diagnostic cut-
points.

There was substantial heterogeneity in the included studies. Sensitivity analyses removing potentially unrepresentative populations in
these studies made little difference to the pooled data estimates.

The majority of included papers had potential for bias, particularly around participant selection and sampling. The quality of reporting
was suboptimal particularly regarding timing of assessments and descriptors of reproducibility and inter-observer variability.

Authors' conclusions

Published  data  suggest  that  if  using  the  IQCODE  for  community  dwelling  older  adults,  the  16  item  IQCODE  may  be  preferable  to  the
traditional  scale  due  to  lesser  test  burden  and  no  obvious  difference  in  accuracy.  Although  IQCODE  test  accuracy  is  in  a  range  that
many  would  consider  'reasonable',  in  the  context  of  community  or  population  settings  the  use  of  the  IQCODE  alone  would  result  in
substantial misdiagnosis and false reassurance. Across the included studies there were issues with heterogeneity, several potential biases
and suboptimal reporting quality.

P L A I N   L A N G U A G E   S U M M A R Y

A structured collateral interview regarding cognition and function (the IQCODE) for assessment of possible dementia

Numbers of people with dementia and other cognitive problems are increasing globally. Early diagnosis of dementia is recommended but
there is no agreement on the best approach or how non-memory specialists should assess patients. A potential strategy is to interview
friends or family of the subject to assess for change in function or cognition. Various methods of this collateral interview are available and
the most commonly used is the Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE). We searched differing databases of
published research for all papers relating to the accuracy of IQCODE for selecting those with dementia. We found eleven studies that tested
diagnostic accuracy of IQCODE in community dwelling individuals, we were able to combine their findings to give a summary result. We
compared two forms of IQCODE questionnaire and found that a short form with fewer questions was just as accurate as the original longer
questionnaire. The overall accuracy of IQCODE was reasonable although not perfect. If IQCODE were to be used on its own for assessing
large populations of older adults, it would label many people with dementia who do not have the disease and also miss the diagnosis in
a substantial proportion.

Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the detection of dementia within community dwelling
populations (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

2

 
 
S U M M A R Y   O F   F I N D I N G S

Summary of findings 1.   Summary of included studies

Study ID

Country

Subjects (n)

IQCODE version

Language

Dementia diag-
nosis

Dementia prevalence N
(%)

Other as-
sessments

Jorm 1994

Australia

Jorm 1996 (psychiatry)

Australia

Kathriarachi 2001

Sri Lanka

Law 1995

Mackinnon 2003

Morales 1995

Morales 1997 (rural)

Morales 1997 (urban)

Senanorong 2001

Srikanth 2006

Yamada 2011

Canada

Australia

Spain

Spain

Spain

Thailand

Australia

Japan

684

144

37

237

646

68

160

97

160

79

423

26 & 16 item

English

DSM IIIr

26 & 16 item

English

ICD9

26 item

Sinhalese

"clinical assess-
ment"

26 item

16 item

French

DSM IIIr

English

DSM IIIr

26 & 17 item

Spanish

DSM IIIr

26 item

26 item

Spanish

DSM IIIr

Spanish

DSM IIIr

16 & 3 item

Thai

DSM IV

n=52

n=11

n=14

n=32

n=36

n=7

n=23

n=11

n=73

n=8

16 item

26 item

English

DSM IV

Japanese

DSM IV

n=112

-

MMSE

MMSE, CDR

MMSE

MMSE

MMSE

MMSE

MMSE

TMSE

S-MMSE

8%

8%

38%

14%

6%

10%

14%

11%

46%

10%

26%

See Characteristics of included studies for more detailed study descriptors.
Abbreviations: DSM - American Psychiatric Associationm Diagnostic and Statistical Manual of Mental Disorders; MMSE - Mini Mental State Examination; AMT - Abbreviated Mental
Test; CDR - Clinical Dementia Rating Scale; TMSE - Thai Mental State Exam; S-MMSE - standardised Mini Mental State Examination.

Summary of findings 2.   Summary of findings table 1

4 What is the accuracy of the Informant Questionnaire for Cognitive Decline in the Elderly (IQCODE) test for detection of dementia using different versions of IQCODE and us-
ing different languages of administration

p
o
p
u
l
a
t
i
o
n
s
(
R
e
v
i
e
w

)

C
o
p
y
r
i
g
h
t

©
2
0
2
1
T
h
e
C
o
c
h
r
a
n
e
C
o

l
l
a
b
o
r
a
t
i
o
n

.

P
u
b

l
i
s
h
e
d
b
y
J
o
h
n
W

i
l
e
y
&
S
o
n
s
,
L
t
d

.

I
n
f
o
r
m
a
n
t
Q
u
e
s
t
i
o
n
n
a
i
r
e
o
n
C
o
g
n
i
t
i
v
e
D
e
c
l
i
n
e
i

n
t
h
e
E
l
d
e
r
l
y
(
I
Q
C
O
D
E
)

f
o
r

t
h
e
d
e
t
e
c
t
i
o
n
o
f
d
e
m
e
n
t
i
a
w

i

i
t
h
n
c
o
m
m
u
n
i
t
y
d
w
e
l
l
i
n
g

3

L
i
b
r
a
r
y

C
o
c
h
r
a
n
e

B
e
t
t
e
r
h
e
a
l
t
h
.

T
r
u
s
t
e
d
e
v
i
d
e
n
c
e
.

I
n
f
o
r
m
e
d
d
e
c
i
s
i
o
n
s
.

C
o
c
h
r
a
n
e
D
a
t
a
b
a
s
e
o
f
S
y
s
t
e
m
a
t
i
c
R
e
v
i
e
w
s

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Population

Community-dwelling older adults, with no restrictions placed on case-mix of included cohort

Setting

Index test

'Community' setting; this setting was intended to represent a population screening context. Many of the included studies, although fulfilling our
pre-specified inclusion criteria, were of selected population groups (for example stroke-survivors; ex-prisoners of war) the effect of these studies
is described in the 'heterogeneity' section of results

Informant Questionnaire for Cognitive Decline in the Elderly (IQCODE) administered to a relevant informant. We restricted analyses to the tradi-
tional 26-item IQCODE and a commonly used short form IQCODE with 16 items

Reference Standard

Clinical diagnosis of dementia made using any recognised classification system

Studies

Cross-sectional studies were included, we did not include case-control studies

Comparative analyses

Test

No. of participants (studies)

Dementia prevalence

Findings

Implications

26 item versus 16 item
IQCODE

total across studies

Total: n=2644

Total n=379

No difference in accuracy.

(10 studies, 11 data sets)

(14%)

26 item n=1075 (7 studies, 8
datasets)

26 item n=210

(20%)

16 item n=169

(11%)

Relative sensitivity of 26-item versus 16-item IQ-
CODE: 1.00 (95% CI 0.91 to 1.11)

Relative specificity of 26 item versus 16-item IQ-
CODE: 0.94 (95% CI 0.82 to 1.09).

Short form IQCODE may be
preferred as lesser test bur-
den with similar accuracy

English language ver-
sus non-English

Total: n=2644

Total: n=379

No significant difference in accuracy.

(10 studies, 11 data sets)

(14%)

English: n=1553

English: n=107

(4 studies)

(6%)

Relative sensitivity of English language versus non-
English language: 1.03 (95% CI 0.91 to 1.16)

Relative specificity of English language versus non-
English language: 1.15 (95% CI 0.98 to 1.34).

IQCODE accuracy is not sub-
stantially influenced by lan-
guage of administration

Non-English: n=272 (25%)

CAUTION: The results on this table should not be interpreted in isolation from the results of the individual included studies contributing to each summary test accuracy
measure. These are reported in the main body of the text of the review

p
o
p
u
l
a
t
i
o
n
s
(
R
e
v
i
e
w

)

C
o
p
y
r
i
g
h
t

©
2
0
2
1
T
h
e
C
o
c
h
r
a
n
e
C
o

l
l
a
b
o
r
a
t
i
o
n

.

P
u
b

l
i
s
h
e
d
b
y
J
o
h
n
W

i
l
e
y
&
S
o
n
s
,
L
t
d

.

I
n
f
o
r
m
a
n
t
Q
u
e
s
t
i
o
n
n
a
i
r
e
o
n
C
o
g
n
i
t
i
v
e
D
e
c
l
i
n
e
i

n
t
h
e
E
l
d
e
r
l
y
(
I
Q
C
O
D
E
)

f
o
r

t
h
e
d
e
t
e
c
t
i
o
n
o
f
d
e
m
e
n
t
i
a
w

i

i
t
h
n
c
o
m
m
u
n
i
t
y
d
w
e
l
l
i
n
g

4

L
i
b
r
a
r
y

C
o
c
h
r
a
n
e

B
e
t
t
e
r
h
e
a
l
t
h
.

T
r
u
s
t
e
d
e
v
i
d
e
n
c
e
.

I
n
f
o
r
m
e
d
d
e
c
i
s
i
o
n
s
.

C
o
c
h
r
a
n
e
D
a
t
a
b
a
s
e
o
f
S
y
s
t
e
m
a
t
i
c
R
e
v
i
e
w
s

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
p
o
p
u
l
a
t
i
o
n
s
(
R
e
v
i
e
w

)

C
o
p
y
r
i
g
h
t

©
2
0
2
1
T
h
e
C
o
c
h
r
a
n
e
C
o

l
l
a
b
o
r
a
t
i
o
n

.

P
u
b

l
i
s
h
e
d
b
y
J
o
h
n
W

i
l
e
y
&
S
o
n
s
,
L
t
d

.

I
n
f
o
r
m
a
n
t
Q
u
e
s
t
i
o
n
n
a
i
r
e
o
n
C
o
g
n
i
t
i
v
e
D
e
c
l
i
n
e
i

n
t
h
e
E
l
d
e
r
l
y
(
I
Q
C
O
D
E
)

f
o
r

t
h
e
d
e
t
e
c
t
i
o
n
o
f
d
e
m
e
n
t
i
a
w

i

i
t
h
n
c
o
m
m
u
n
i
t
y
d
w
e
l
l
i
n
g

5

Summary of findings 3.   Summary of findings table 2

What is the accuracy of the Informant Questionnaire for Cognitive Decline in the Elderly (IQCODE) test for detection of dementia when differing thresholds are used to define
IQCODE positive cases

Population

Community-dwelling older adults, with no restrictions placed on case-mix of included cohort

Setting

Index test

'Community' setting; this setting was intended to represent a population screening context. Many of the included studies, although fulfilling our
pre-specified inclusion criteria, were of selected population groups (for example stroke-survivors; ex-prisoners of war) the effect of these studies
is described in the 'heterogeneity' section of results

Informant Questionnaire for Cognitive Decline in the Elderly (IQCODE) administered to a relevant informant. We restricted analyses to the tradi-
tional 26-item IQCODE and a commonly used short form IQCODE with 16 items

Reference Standard

Clinical diagnosis of dementia made using any recognised classification system

Studies

Cross-sectional studies were included, we did not include case-control studies

Test

Summary accuracy (95%CI)

No. of participants
(studies)

Dementia prevalence

Implications

n=2644

(10 studies, 11
datasets)

n=379

(14%)

IQCODE cut-off 3.3 or
nearest

sensitivity: 0.80

(95% CI 0.75 to 0.85)

specificity: 0.85

(95% CI 0.78 to 0.90)

positive LR: 5.27

(95% CI 3.70 to 7.50)

negative LR: 0.23

(95% CI 0.19 to 0.29)

IQCODE cut-off 3.3

sensitivity: 0.83

n=1232

n=112 (9%)

(95% CI 0.74 to 0.90)

specificity: 0.80

(95% CI 0.70 to 0.88)

(5 studies, 6 datasets)

Quality and comments

There is no obvious preferred cut-off for
IQCODE accuracy, within the threshold
values commonly used in clinical practice
and research.

So we focus on the summary data

across all cut-points.

The dementia prevalence across studies

is higher than would be expected

for this population.

Using the accuracy figures

re-calculating for a typical population;

In the UK 9.9 million people are aged over
65,

current estimates are of around 6.6% de-
mentia prevalence.

L
i
b
r
a
r
y

C
o
c
h
r
a
n
e

B
e
t
t
e
r
h
e
a
l
t
h
.

T
r
u
s
t
e
d
e
v
i
d
e
n
c
e
.

I
n
f
o
r
m
e
d
d
e
c
i
s
i
o
n
s
.

C
o
c
h
r
a
n
e
D
a
t
a
b
a
s
e
o
f
S
y
s
t
e
m
a
t
i
c
R
e
v
i
e
w
s

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
p
o
p
u
l
a
t
i
o
n
s
(
R
e
v
i
e
w

)

C
o
p
y
r
i
g
h
t

©
2
0
2
1
T
h
e
C
o
c
h
r
a
n
e
C
o

l
l
a
b
o
r
a
t
i
o
n

.

P
u
b

l
i
s
h
e
d
b
y
J
o
h
n
W

i
l
e
y
&
S
o
n
s
,
L
t
d

.

I
n
f
o
r
m
a
n
t
Q
u
e
s
t
i
o
n
n
a
i
r
e
o
n
C
o
g
n
i
t
i
v
e
D
e
c
l
i
n
e
i

n
t
h
e
E
l
d
e
r
l
y
(
I
Q
C
O
D
E
)

f
o
r

t
h
e
d
e
t
e
c
t
i
o
n
o
f
d
e
m
e
n
t
i
a
w

i

i
t
h
n
c
o
m
m
u
n
i
t
y
d
w
e
l
l
i
n
g

6

positive LR: 4.25

(95% CI 2.75 to 6.56)

negative LR: 0.21

(95% CI 0.14 to 0.32)

IQCODE cut-off 3.4

sensitivity: 0.84

(95% CI 0.70 to 0.93)

specificity: 0.80

(95% CI 0.65 to 0.90)

positive LR: 4.25

(95% CI 2.47 to 7.90)

negative LR: 0.19

(95% CI 0.10 to 0.35)

IQCODE cut-off 3.5

sensitivity: 0.82

(95% CI 0.75 to 0.87)

specificity: 0.84

(95% CI 0.80 to 0.88)

positive LR: 5.09

(95% CI 4.08 to 6.33)

negative LR: 0.22

(95% CI 0.16 to 0.29)

IQCODE cut-off 3.6

sensitivity: 0.78

(95% CI 0.68 to 0.86)

specificity: 0.87

(95% CI 0.71 to 0.95)

positive LR: 6.00

(95% CI 2.72 to 13.26)

n=988

(3 studies)

n=136 (14%)

n=1144

(3 studies)

n=178 (16%)

n=1215

(3 studies)

n=180 (15%)

At the IQCODE accuracy calculated,

using IQCODE alone to "screen" for de-
mentia

would result in:

87,120 people with dementia not being
picked up

and 1,314,660 dementia free people being
given a possible diagnosis of dementia.

L
i
b
r
a
r
y

C
o
c
h
r
a
n
e

B
e
t
t
e
r
h
e
a
l
t
h
.

T
r
u
s
t
e
d
e
v
i
d
e
n
c
e
.

I
n
f
o
r
m
e
d
d
e
c
i
s
i
o
n
s
.

C
o
c
h
r
a
n
e
D
a
t
a
b
a
s
e
o
f
S
y
s
t
e
m
a
t
i
c
R
e
v
i
e
w
s

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
negative LR: 0.25

(95% CI 0.18 to 0.34)

CAUTION: The results on this table should not be interpreted in isolation from the results of the individual included studies contributing to each summary test accuracy
measure. These are reported in the main body of the text of the review

p
o
p
u
l
a
t
i
o
n
s
(
R
e
v
i
e
w

)

C
o
p
y
r
i
g
h
t

©
2
0
2
1
T
h
e
C
o
c
h
r
a
n
e
C
o

l
l
a
b
o
r
a
t
i
o
n

.

P
u
b

l
i
s
h
e
d
b
y
J
o
h
n
W

i
l
e
y
&
S
o
n
s
,
L
t
d

.

I
n
f
o
r
m
a
n
t
Q
u
e
s
t
i
o
n
n
a
i
r
e
o
n
C
o
g
n
i
t
i
v
e
D
e
c
l
i
n
e
i

n
t
h
e
E
l
d
e
r
l
y
(
I
Q
C
O
D
E
)

f
o
r

t
h
e
d
e
t
e
c
t
i
o
n
o
f
d
e
m
e
n
t
i
a
w

i

i
t
h
n
c
o
m
m
u
n
i
t
y
d
w
e
l
l
i
n
g

7

L
i
b
r
a
r
y

C
o
c
h
r
a
n
e

B
e
t
t
e
r
h
e
a
l
t
h
.

T
r
u
s
t
e
d
e
v
i
d
e
n
c
e
.

I
n
f
o
r
m
e
d
d
e
c
i
s
i
o
n
s
.

C
o
c
h
r
a
n
e
D
a
t
a
b
a
s
e
o
f
S
y
s
t
e
m
a
t
i
c
R
e
v
i
e
w
s

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

B A C K G R O U N D

Dementia is a substantial and growing public health concern (Ferri
2005). Depending on the case definition employed, contemporary
estimates  of  dementia  prevalence  in  the  United  States  are  in  the
range  of  2.5  to  4.5  million  individuals  (Hebert  2003).  Dementia  is
predominantly a disease of older adults, with a 5% prevalence in
adults aged over 60 years, increasing to up to 50% in adults aged
over  85  years  (Ferri  2005).  Changes  in  population  demographics
will  result  in  increased  absolute  and  proportional  numbers  of
older  adults  and  will  be  accompanied  by  increases  in  dementia
incidence  and  prevalence,  albeit  the  extent  of  this  increase  is
debated  (Matthews  2013).  Dementia  is  not  limited  to  'Western'
nations  and  an  increasing  prevalence  is  particularly  marked  in
countries such as China and India (Ferri 2005).

Given  the  projected  global  increase  in  dementia  prevalence,
there is a potential tension between the clinical requirements for
robust  diagnosis  at  the  individual  patient  level  and  the  need  for
equitable, easy access to diagnosis at a population level. The ideal
would be expert, multidisciplinary assessment informed by various
supplementary investigations. Such an approach may be possible
in a secondary or tertiary care setting, however, in a community or
primary care setting the population is too large and the prevalence
of the disease will be low relative to the more specialist memory-
clinic setting.

In  practice  a  two-stage  process  is  often  employed  and  initial
screening  or  'triage'  assessments,  suitable  for  use  by  non-
specialists,  are  used  to  select  those  patients  who  require
further  detailed  assessment  (Boustani  2003).  Various  tools  for
initial  cognitive  screening  or  case  finding  have  been  described
(Brodaty  2002;  Folstein  1975;  Galvin  2005).  However,  regardless
of  the  methods  employed  there  is  scope  for  improvement  with
observational studies suggesting that many patients with dementia
are not diagnosed (Chodosh 2004; Valcour 2000).

Initial  assessment  often  takes  the  form  of  brief,  direct  cognitive
testing.  Using  this  method  a  single  test  can  only  provide  a
'snapshot'  of  cognitive  function.  However,  a  defining  feature
of  dementia  is  cognitive  or  neuropsychological  change  over
time.  Patients  themselves  may  struggle  to  make  an  objective
assessment  of  personal  change  over  a  period  of  years  and  so  an
attractive approach is to question collateral sources with sufficient
knowledge of the patient. Various terms have been used to describe
the  person(s)  providing  descriptions  of  the  patient's  cognition
including  proxy,  collateral,  informant,  carer  etc.  We  should  make
no assumptions about the relationship of the person providing the
description and for consistency throughout the text we use the term
informant.

Informant-based  interviews  have  been  described  that  aim  to
retrospectively assess change in function over a period of time. An
instrument  prevalent  in  research  and  clinical  practice  is  the
Informant  Questionnaire  on  Cognitive  Decline  in  the  Elderly
(IQCODE), and this is the focus of our review.

There  is  no  consensus  on  the  optimal  test  for  dementia  and
choice of test is currently dictated by experience with a particular
instrument, time constraints and training. A better understanding
of  the  diagnostic  properties  of  various  strategies  would  allow  for
an informed approach to testing. Critical evaluation of the evidence
base  for  short  dementia  tests  or  other  diagnostic  markers  is  of

Cochrane Database of Systematic Reviews

major  importance.  Without  a  robust  synthesis  of  the  available
information there is the risk that future research, clinical practice
and policy will be built on erroneous assumptions about diagnostic
validity.

Target condition being diagnosed

The  target  condition  for  this  diagnostic  test  accuracy  review  is
dementia (clinical diagnosis).

is  a  syndrome  characterised  by  cognitive  or
Dementia 
neuropsychological  decline  sufficient  to  interfere  with  usual
functioning. The neurodegeneration and clinical manifestations of
dementia are progressive and at present there is no 'cure', although
numerous  interventions  to  slow  or  arrest  cognitive  decline  have
been studied.(Birks 2006; Clare 2003; McShane 2006).

Dementia  remains  a  clinical  diagnosis,  based  on  a  history  from
the patient and suitable informant sources and direct examination
including cognitive assessment. Expert committees have described
criteria  for  diagnosis  of  the  dementia  syndrome  and  its  various
subtypes (Erkinjuntti 2000; McKeith 2005; McKhann 1984; McKhann
2001;  Roman  1993).  Various  clinical  diagnostic  protocols  are
available and although there are slight variations in European and
American  guidance,  core  features  are  common  to  all  diagnostic
criteria (McKhann 2011) (Appendix 1).

We recognise that there is no universally accepted, gold standard
dementia  diagnostic  strategy.  We  chose  expert  clinical  diagnosis
as  our  gold  standard  (reference  standard)  for  describing  IQCODE
accuracy  as  we  believe  this  is  most  in  keeping  with  current
diagnostic  criteria  and  best  practice.  Previous  studies  have  used
neuropathology  as  a  gold  standard.  For  the  purpose  of  testing
diagnostic  accuracy  in  large  unselected  populations,  limiting
analysis  to  those  studies  with  neuropathological  confirmed
diagnosis  is  likely  to  yield  limited  and  highly  selected  data
(Savva  2009).  Criteria  for  diagnosis  of  dementia  are  evolving  in
line  with  improvements  in  our  understanding  of  the  underlying
pathophysiological  processes.  Various  biomarkers  based  on
biological fluid assays or functional and quantitative neuroimaging
have shown promise but to date they are not accepted or validated
as independent diagnostic tests (McKhann 2011; Noel-Storr 2012).

The label of dementia encompasses varying pathologies of which
Alzheimer’s  disease  is  the  most  common.  For  our  reference
standard  of  clinical  diagnosis,  we  accept  a  dementia  diagnosis
made according to any of the internationally accepted diagnostic
criteria,  with  exemplars  being  the  various  iterations  of  the  World
Health  Organization  International  Classification  of  Diseases  (ICD)
and the American Psychiatric Association Diagnostic and Statistical
Manual  of  Mental  Disorders  (DSM)  for  all  cause  dementia  and
subtypes  (Appendix  1).  We  also  recognise  the  various  diagnostic
criteria  available  for  specific  dementia  subtypes  that  is  the
National  Institute  of  Neurological  and  Communicative  Disorders
and  Stroke  and  the  Alzheimer's  Disease  and  Related  Disorders
Association  (NINCDS-ADRDA)  criteria  for  Alzheimer’s  dementia
(McKhann 1984); McKeith criteria for Lewy Body dementia (McKeith
2005); Lund criteria for frontotemporal dementias (McKhann 2001);
and  the  National  Institute  of  Neurological  Disorders  and  Stroke
- Association Internationale pour la Recherche et l'Enseignement
en  Neurosciences  (NINDS-AIREN)  criteria  for  vascular  dementia
(Roman  1993).  Diagnostic  criteria  are  continually  evolving  in  line
with a better clinical and scientific understanding of dementia, for

Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the detection of dementia within community dwelling
populations (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

8

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

example at the time of review the fifth edition of DSM was in pre-
release.

Index test(s)

We chose the Informant Questionnaire on Cognitive Decline in the
Elderly (IQCODE) (Jorm 1988) as our index test of interest.

The  IQCODE  was  originally  described  as  a  26-item  informant
questionnaire  designed  to  retrospectively  ascertain  change  in
cognitive and functional performance over a 10-year time period
(Jorm 1988). IQCODE is designed as a brief assessment for potential
dementia,  usually  administered  as  a  questionnaire  given  to  the
relevant proxy. For each item the chosen proxy scores change on
a five-point ordinal hierarchical scale with responses ranging from
1: “has become much better” to 5: “has become much worse”. This
gives  a  sum-score  of  26  to  130  that  can  be  averaged  by  the  total
number of completed items to give a final score of 1.0 to 5.0, where
higher scores indicate greater decline.

First described in 1989, use of IQCODE is prevalent in both clinical
practice and research (Holsinger 2007) and the questionnaire has
been translated into several languages (www.anu.edu.au/iqcode/).
IQCODE  has  a  number  of  features  that  make  it  attractive  for
clinical and research use. The questions used have an immediacy
and  relevance  that  is  likely  to  appeal  to  users.  Assessment  and
(informant) scoring takes around five to seven minutes and as the
scale is not typically interviewer administered it requires minimal
training  in  application  and  scoring  (Holsinger  2007).  Proponents
of  IQCODE  suggest  several  potentially  favourable  properties  of
the IQCODE when compared to standard direct assessments. The
IQCODE may be less prone to bias from cultural norms and previous
levels  of  education;  the  scale  has  good  inter-rater  reliability;  and
internal  consistency  is  uniformly  high  with  Cronbach’s  alpha  in
the range 0.93 to 0.97 (Jorm 1989A). Validation work has included
validation against measures of cognitive change; neuropathology;
neuroimaging  and  neuropsychological  assessment  (Cordoliani-
Mackowiak 2003; Jorm 2000A; Rockwood 1998).

A  shortened  16-item  version  is  available;  this  modified  IQCODE
is  common  in  clinical  practice  and  has  been  recommended  as
the  preferred  IQCODE  format  (Jorm  2004).  Further  modifications
to  IQCODE  are  described  including  fewer  items  and  assessment
over shorter time periods. For our analysis we chose to include all
versions of IQCODE but present results for the original and modified
scales separately in the first instance. In this text, the term IQCODE
refers to the original 26-item questionnaire as described by Jorm
(Jorm 1988).

IQCODE cut-off scores used to define test positivity vary with the
demographics  of  the  population  and  the  reason  for  testing.  In
the  original  development  and  validation  work,  normative  data
were  described  with  a  total  score  of  >  93  or  average  score  of  >
3.31  indicative  of  cognitive  impairment  (Jorm  1988).  There  is  no
consensus  on  the  optimal  threshold  and  various  authors  have
described improved diagnostic accuracy with other cut-offs.

The full 26 and 16-item versions of ICQODE with scoring rules are
available as appendices (Appendix 2; Appendix 3).

Clinical pathway

A  key  element  of  effective  management  in  dementia  is  robust
diagnosis. Recent guidelines place emphasis on early diagnosis to

Cochrane Database of Systematic Reviews

facilitate improved management and to allow informed discussions
and planning with patients and carers. The utility of screening for
an  early,  unprompted  diagnosis  of  dementia  remains  a  subject
of  debate.  There  are  major  pressures  for  early  diagnosis  from
third sector organisations, patient representative groups, and the
pharmaceutical  industry;  and  in  certain  countries  opportunistic
cognitive  screening  or  case-finding  is  suggested  (Brunet  2012;
Cordell 2013).

We recognise the importance of healthcare setting and populations
in describing test properties. We have defined a series of settings
and  populations  for  reviews;  these  are  based  on  the  reason  for
performing  the  index  (IQCODE)  test  and  the  likely  prevalence  of
dementia.

Studies can be based in secondary care, that is where a referral has
already been made by a healthcare professional and where there
may have been some form of cognitive screening or selection.

In the general practice or primary care setting, patients generally
self-present  to  a  non-specialist  service  because  of  subjective
memory complaints, usually with no prior cognitive testing. In this
setting  the  purpose  of  cognitive  testing  is  to  triag'  individuals  to
inform decisions about onward specialist referral. 

A  study  in  a  community  (population)  setting  will  generally  be
an  unselected  cohort  with  no  previous  cognitive  assessment.
The  purpose  of  community  cognitive  testing  may  be  population
screening,  or  to  inform  epidemiological  studies.  Our  intention
with  the  community  setting  was  to 
include  those  studies
closest to population level screening. Methodologies for selecting
representative  community  samples  differ  and  for  this  review  we
adopted  an  inclusive  approach  in  the  first  instance,  including
studies  where  the  populations  were  community  dwelling  and
not  selected  on  the  basis  of  cognitive  scores  or  symptoms.  We
would expect lower prevalence of disease in the community setting
compared  to  other  settings.  This  is  an  important  methodological
point  as  in  certain  studies  researchers  'enrich'  a  community
population  with  dementia  cases.  This  process  can  artificially
improve test accuracy and does not allow for description of those
metrics that relate to population prevalence, for example positive
or negative predictive value.

For  this  review  we  described  the  test  accuracy  of  IQCODE  when
used in a community setting. For consistency through the review
we have used the term community. Reviews describing studies in
other settings will also be available in due course.

Prior test(s)

For  a  review  in  a  community  setting,  we  would  expect  that
the  majority  of  individuals  included  will  have  had  no  previous
assessment  for  cognitive  problems.  We  did  not  include  studies
where  recruitment  was  based  on  results  of  previous  cognitive
test(s).

Role of index test(s)

Although  we  use  the  term  diagnosis  in  this  review,  we  recognise
that in practice IQCODE alone is not sufficient to make a diagnosis.
Rather IQCODE is used as an initial case finding, triage, or screening
test  that  can  inform  the  need  for  further  assessment  or  assist
with diagnosis in conjunction with direct patient assessment and
investigations.  For  ease  of  understanding  and  consistency  with

Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the detection of dementia within community dwelling
populations (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

9

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

other  reviews  we  used  the  term  diagnostic  accuracy  to  infer
'accuracy of IQCODE test for suggesting a possible dementia case'.

Alternative test(s)

are 

rely 

normative 

comparing 

assessment 
usually 

dementia 
these 
that 
cognitive 
data 

have
tools 
performance-
single
on 
testing 
against  population-
(http://onlinelibrary.wiley.com/

other 
Several 
been 
described, 
based  measures 
or  multi-domain 
specific 
doi/10.1002/14651858.CD010079/full#CD010079-
bbs2-0005#CD010079-bbs2-0005;  http://onlinelibrary.wiley.com/
doi/10.1002/14651858.CD010079/full#CD010079-
bbs2-0006#CD010079-bbs2-0006;  http://onlinelibrary.wiley.com/
doi/10.1002/14651858.CD010079/full#CD010079-
bbs2-0018#CD010079-bbs2-0018).  There  are  fewer 
informant
interviews  available.  An  alternative  to  IQCODE  that  is  popular
in  North  America  is  the  eight-item  Interview  to  Differentiate
Aging  and  Dementia 
(http://onlinelibrary.wiley.com/
doi/10.1002/14651858.CD010079/full#CD010079-
bbs2-0014#CD010079-bbs2-0014).

(AD-8) 

For  this  review  we  did  not  consider  other  cognitive  screening
or  assessment  tools  and  have  chosen  not  to  include  other
tests  as  comparators.  Currently  there  is  no  standard  practice
biomarker or neuropsychological test and so we felt that making
decisions  on  meaningful  comparators  was  premature.  Where  a
paper describes IQCODE with in-study comparison against another
tool, we included the IQCODE data only. Where the IQCODE code
was  used  in  combination  with  another  tool,  we  included  the
IQCODE data only.

Our  IQCODE  diagnostic  studies  form  part  of  a  larger  body  of
work  describing  the  test  accuracy  of  all  commonly  used  scales
and  Cochrane  diagnostic  test  accuracy  (DTA)  reviews  specific  to
the  AD-8;  Abbreviated  Mental  Test  (AMT);  Clock  Drawing  Test
(CDT);  Mini-Cognitive  Assessment  Instrument  (Mini-Cog);  Mini-
Mental State Examination (MMSE); Montreal Cognitive Assessment
(MoCA) and General Practitioner assessment of Cognition (GPcog)
are  planned  or  in  production  (http://onlinelibrary.wiley.com/
doi/10.1002/14651858.CD010079/full#CD010079-
sec2-0013#CD010079-sec2-0013).

Rationale

Clinical properties of a dementia test should not be assumed and
formal  testing  of  sensitivity,  specificity  and  other  properties  of
IQCODE should be performed and collated before the tool can be
recommended. 

IQCODE  is  commonly  used  in  practice  and  research;  it  is  used
internationally and is one of only a few validated informant-based
tools.  Literature  describing  test  accuracy  of  IQCODE  in  different
settings  is  available,  although  some  of  these  studies  have  been
modest  in  size.  Thus  a  systematic  review  and,  if  possible,  meta-
analysis of the diagnostic test accuracy of IQCODE is warranted.

O B J E C T I V E S

Cochrane Database of Systematic Reviews

Secondary objectives

Where data were available, we planned to describe the following.

1. The  diagnostic  accuracy  of  IQCODE  at  various  pre-specified
thresholds.  We  recognize  that  various  thresholds  or  cut-off
scores have been used to define IQCODE test positive states. We
described  the  test  accuracy  of  IQCODE  for  the  following  cut-
off  scores  (rounded  where  necessary):  3.3,  3.4,  3.5,  3.6.  These
thresholds have been chosen to represent the range of cut-offs
that are commonly used in practice and research; we have been
inclusive in our choice of cut-off to maximize available data for
review.

2. Accuracy  of  IQCODE  for  diagnosis  of  the  commonest  specific

dementia subtype, Alzheimer’s disease dementia.

3. Effects of heterogeneity (see below) on the reported diagnostic

accuracy of IQCODE.

Our focused study question, restricting this review to a community
setting,  was  designed  to  remove  potential  heterogeneity  relating
to  study  design  and  setting.  Other  sources  of  heterogeneity  in
dementia  studies  such  as  treatment,  intervention  or  duration  of
follow-up  are  not  applicable  to  this  review  and  were  considered
within  the  inclusion  and  exclusion  criteria.  The  properties  of  a
tool  describe  the  behaviour  of  the  instrument  under  particular
circumstances.  Thus  for  our  assessment  of  potential  sources  of
heterogeneity  (where  data  allowed),  we  collated  data  on  key
features  of  the  study  population  namely  age;  features  of  the
index test, namely language of administration and IQCODE format;
features of the reference standard, namely diagnostic criteria used;
and diagnostic methodology.

M E T H O D S

Criteria for considering studies for this review

Types of studies

All  studies  of  community-based  cohorts  were  potentially  eligible
for  the  review.  As  discussed,  we  used  the  rubric  'community'  to
include studies of community dwelling older adults, unselected on
the basis of cognitive scores or symptoms.

Many  studies  that  assess  test  properties  use  a  case  control
methodology.  This  approach  is  prone  to  a  number  of  potential
biases  and  may  give  artificially  high  values  for  test  accuracy.  For
certain studies, in particular where populations are 'enriched' with
dementia cases, case control methodology may be employed but
not explicitly stated. We elected to include potential case control
studies in our initial screening review of the search results and then
assess studies on a case by case basis. Where case control or study
enriching was employed we did not include these in the summary
data or pool these data with other studies.

Case  studies  or  samples  with  very  small  numbers  (chosen  as  10
participants  or  less  for  the  purposes  of  this  review)  were  not
included.

Participants

Our  primary  obective  was  to  determine  the  accuracy  of  the
informant-based questionnaire IQCODE, for detection of dementia
within community dwelling populations.

All  community-dwelling  adults  (aged  over  18  years)  were
potentially  eligible.  We  suspected  that  the  majority  of  included
participants in the eligible studies would be aged over 65 years.

Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the detection of dementia within community dwelling
populations (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

10

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Our  definition  of  a  community-based  study  setting  was  a  study
where  participants  were  community  dwelling,  had  not  been
referred, had not had extensive cognitive testing and had not self-
presented  for  assessment  of  subjective  memory  problems.  We
anticipated that studies would largely be of unselected community-
dwelling  adults;  this  cohort  is  itself  heterogeneous.  We  did  not
predefine  exclusion  criteria  relating  to  the  'case-mix'  of  the
population studied but assessed applicability for each study. Where
a  population  was  community  dwelling  and  unselected  on  the
basis  of  cognition  but  was  potentially  not  representative  of  the
population, for example a study with a focus on stroke-survivors,
we chose to explore the effect of these studies on the findings using
sensitivity analyses.

Index tests

Studies had to include (not necessarily exclusively) IQCODE used as
an informant questionnaire.

IQCODE has been translated into various languages. The properties
of  a  translated  IQCODE  in  a  cohort  of  non-English  speakers
may  differ  from  the  properties  of  the  original  English  language
questionnaire.  We  collected  data  on  the  principle  language  used
for  IQCODE  assessment  in  studies  to  allow  for  assessment  of
heterogeneity in relation to language.

Since  its  original  description  modifications  to  the  administration
of  IQCODE  have  been  described  (Jorm  2004).  Shorter  forms  of
informant questionnaires that test fewer domains are available and
properties  may  differ  from  the  original  26-item  IQCODE  tool.  We
included  all  such  versions  of  IQCODE  but  presented  separate
analysis  limited  to  the  commonest  26  and  16-item  versions.  A
modified IQCODE for self-assessment has been described. As our
interest was informant interviews, self-assessment IQCODE was not
included in the review (Cullen 2007).

Target conditions

Papers  reporting  any  clinical  diagnosis  of  all  cause  (unspecified)
dementia  were  potentially  eligible  for  inclusion.  Defining  a
particular  dementia  subtype  was  not  required  although  where
available, these data were recorded.

Reference standards

Our  reference  standard  was  clinical  diagnosis  of  dementia.  We
recognise  that  clinical  diagnosis  itself  has  a  degree  of  variability
but this is not unique to dementia studies and does not invalidate
the  basic  diagnostic  test  accuracy  approach.  Our  definition  of
clinical diagnosis included all cause (unspecified) dementia, using
any  recognised  diagnostic  criteria  (for  example  ICD-10;  DSM-IV).
The dementia diagnosis could specify a pathological subtype and
all  dementia  subtypes  were  included  (examples  McKeith  2005;
McKhann 1984; McKhann 2001; Roman 1993). Clinicians may have
used imaging, pathology or other data to aid diagnosis, however,
diagnosis  based  only  on  these  data  without  corresponding
clinical assessment were not included. We recognise that different
iterations of diagnostic criteria may not be directly comparable and
that  diagnosis  may  vary  with  the  degree  or  manner  in  which  the
criteria have been operationalised (for example individual clinician
versus algorithm versus consensus determination) and so data on
method  and  application  of  dementia  diagnosis  was  collected  for
each study.

Cochrane Database of Systematic Reviews

We  did  not  set  criteria  relating  to  severity  or  stage  of  dementia
diagnosis,  instead  any  clinical  diagnosis  of  dementia  (not  mild
cognitive impairment or its equivalents) was classified. We planned
to  explore  stage  or  severity  of  dementia  as  a  potential  source  of
heterogeneity.

Search methods for identification of studies

We  used  a  variety  of  information  sources  to  ensure  all  relevant
studies  were  included.  Terms  for  electronic  database  searching
were  devised  in  conjunction  with  the  Trials  Search  Co-ordinator
at the Cochrane Dementia and Cognitive Improvement Group. As
part of a body of work looking at cognitive assessment tools, we
created a sensitive search strategy designed to capture dementia
test accuracy studies. The output of the searches was then assessed
to  select  those  papers  that  could  be  pertinent  to  IQCODE,  with
further selection for directly relevant papers and those papers with
a community (population) focus.

Electronic searches

We  searched  ALOIS,  the  specialised  register  of  the  Cochrane
Dementia and Cognitive Improvement Group (which includes both
intervention and diagnostic accuracy studies), MEDLINE (OvidSP),
EMBASE  (OvidSP),  PsycINFO  (OvidSP),  BIOSIS  (OvidSP),  ISI  Web
of  Science  and  Conference  Proceedings  (ISI  Web  of  Knowledge),
CINAHL  (EBSCOhost)  and  LILACS  (BIREME).  See  Appendix  4  and
Appendix 5 for the search strategies. The final search date was 28
January 2013.

We  also  searched  sources  specific  to  diagnostic  accuracy  and
healthcare assessment:

• MEDION database (Meta-analyses van Diagnostisch Onderzoek:

www.mediondatabase.nl);

• DARE  (Database  of  Abstracts  of  Reviews  of  Effects  via  The

Cochrane Library);

• HTA  Database  (Health  Technology  Assessments  Database  via

The Cochrane Library);

• ARIF  database  (Aggressive  Research 

Intelligence  Facility:

www.arif.bham.ac.uk).

We did not apply any language or date restrictions to the electronic
searches. Translation services were used as necessary.

Initial  screening  of  the  search  results  was  performed  by  a  single
researcher from the Cochrane Dementia and Cognitive Impairment
Group  with  extensive  experience  of  systematic  reviews  (ANS).
All  subsequent  assessments  of  search  results,  based  either  on
assessment  of  titles,  abstracts  or  full  text,  were  performed  by
independent paired assessors (TQ, PF).

Searching other resources

Grey  literature:  'grey'  literature  was  identified  through  searching
conference proceedings on EMBASE (OvidSP) and through the ISI
Web of Knowledge platform.

Handsearching: we did not perform handsearching. The evidence
base on handsearching for DTAs is not yet known and there is no
clear guidance on whether handsearching is worthwhile.

Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the detection of dementia within community dwelling
populations (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

11

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Reference lists: we checked the reference lists of all relevant studies
and reviews in the field for further possible titles and repeated the
process until no new titles were found (Greenhalgh 2005).

Correspondence:  we  contacted  research  groups  who  have
published  or  are  conducting  work  on  the  IQCODE  for  dementia
diagnosis, informed by results of the initial search.

Relevant  additional  studies  were  searched  for  in  PubMed  using
the  related  article  feature.  Relevant  studies  were  examined  in
the  citation  databases  of  Science  Citation  Index  and  Scopus  to
ascertain any further relevant studies.

Data collection and analysis

Selection of studies

One review author (ANS) screened for relevance all titles generated
by the initial electronic database searches. The initial search was
a  sensitive,  generic  search  designed  to  include  many  potential
dementia  screening  tools.  Titles  potentially  relevant  to  IQCODE
were selected by two review authors (ANS, TQ). All further reviews
of  studies  and  selection  were  performed  by  two  independent
researchers  (TQ,  PF).  The  potential  IQCODE  related  titles  were
reviewed  and  all  eligible  studies  were  assessed  as  abstracts;
potentially relevant studies were assessed against inclusion criteria
as full manuscripts. Disagreement was resolved by discussion, with
potential to involve a third author (DJS) as arbitrator if necessary.

We  adopted  a  hierarchical  approach  to  exclusion,  first  excluding
studies on the basis of index test and reference standard and then
on the basis of sample size and study data. Finally, we assessed all
IQCODE papers with regard to setting.

Where  a  study  may  have  included  useable  data  but  these  were
not  presented  in  the  published  manuscript  (labelled  as  data  not
suitable  for  analysis  on  flowchart),  we  contacted  the  authors
directly  to  request  further  information.  If  the  same  data  set  was
presented in more than one paper we included the primary paper.

Cochrane Database of Systematic Reviews

For  each  included  paper,  the  flow  of  participants  (numbers
recruited, included, assessed) was detailed in a flow diagram.

Assessment of methodological quality

As  well  as  describing  test  accuracy,  an  important  goal  of  the
diagnostic test accuracy (DTA) process is to improve study design
and reporting in dementia diagnostic studies. For this reason we
assessed both methodological and reporting quality.

Quality of study reporting was assessed using the STARD checklist
(Bossuyt  2003)  (Appendix  6).  We  recognise  that  a  dementia-
specific  extension  to  complement  STARD  (STARDdem)  (http://
starddem.org/)  is  proposed,  however  the  content  of  STARDdem
was  not  finalised  at  the  time  of  this  analysis.  STARD  data  were
tabulated and presented as an appendix to the review.

tool 

We  assessed  the  methodological  quality  of  each  study  using
the  QUADAS-2 
(http://www.bris.ac.uk/quadas/quadas-2)
(Appendix  7).  This  tool  incorporates  domains  specific  to  patient
selection; 
index  test;  reference  standard;  and  patient  flow.
Each  domain  is  assessed  for  risk  of  bias  and  the  first  three
domains are also assessed for applicability. Operational definitions
describing  the  use  of  QUADAS-2  are  detailed  in  Appendix  7.
To  create  QUADAS-2  anchoring  statements  specific  to  studies  of
dementia test accuracy, we convened a multidisciplinary review of
various test accuracy studies with a dementia reference standard
(Appendix 8).

Both  assessments  were  performed  by  paired  independent  raters
(TJQ, PF) who were blinded to each other’s scores. Disagreement
was resolved by further review and discussion with the potential to
involve a third author (DJS) as arbitrator if necessary.

QUADAS-2  data  were  not  used  to  form  a  summary  quality  score,
rather  we  chose  to  present  a  narrative  summary  describing  the
numbers of studies that found high, low or unclear risk of bias and
concerns  regarding  applicability  with  corresponding  tabular  and
graphical displays.

We detailed the study selection process in a PRISMA flow diagram.

Statistical analysis and data synthesis

Data extraction and management

Data  were  extracted  to  a  study-specific  pro  forma  that  included
clinical  and  demographic  details  of  the  participants;  details  of
IQCODE  administration;  and  details  of  the  dementia  diagnosis
process.  The  pro  forma  was  piloted  against  two  of  the  included
papers before use.

Where  IQCODE  data  were  given  for  a  number  of  cut-points,  we
extracted data for each of our pre-specified cut-points: 3.3, 3.4, 3.5,
3.6.  Where  thresholds  were  described  to  two  decimal  places,  we
chose the cut-point closest to the point of interest (that is all scores
less  than  3.35  would  be  scored  as  3.3;  all  scores  3.35  or  greater
would be scored as 3.4. Data were extracted to a standard two by
two table.

Data  extraction  was  performed  independently  by  review  authors
(TQ, PF). Authors were based in differing centres and were blinded
to  each  other's  data  until  extraction  was  complete.  Data  pro
formas  were  then  compared  and  discussed  with  reference  to  the
original papers. Disagreement in data extraction was resolved by
discussion,  with  the  potential  to  involve  a  third  author  (DJS)  as
arbitrator if necessary.

We were principally interested in the test accuracy of IQCODE for the
dichotomous variable dementia or no dementia. Thus, we applied
the  current  DTA  framework  for  analysis  of  a  single  test  to  fit  the
extracted  data  to  a  standard  two  by  two  table  showing  binary
test  results  cross-classified  with  the  binary  reference  standard.
This  process  was  repeated  for  each  of  our  pre-specified  IQCODE
threshold scores.

We  used  RevMan  5.2  (RevMan  2011)  to  calculate  sensitivity,
specificity and their 95% confidence intervals (CIs) from the two by
two tables abstracted from the included studies. These data were
presented graphically in forest plots to allow basic visual inspection
of  individual  studies  only.  Standard  forest  plots  with  graphical
representation of summary estimates are not suited to quantitative
synthesis  of  DTA  data.  Using  software  additional  to  RevMan  (SAS
release  9.1)  we  used  the  bivariate  method  to  calculate  summary
values  within  each  pre-specified  cut-off.  The  bivariate  methods
(Reitsma  2005)  enabled  us  to  calculate  summary  estimates  of
sensitivity and specificity while correctly dealing with the different
sources  of  variation:  (1)  imprecision  by  which  sensitivity  and
specificity  have  been  measured  within  each  study;  (2)  variation

Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the detection of dementia within community dwelling
populations (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

12

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

beyond  chance  in  sensitivity  and  specificity  between  studies;  (3)
any correlation that might exist between sensitivity and specificity.

The results for each chosen threshold were described as sensitivity
and  specificity  and  all  accuracy  measures  were  estimated  with
their 95% CI. Where data allowed, we chose to present individual
study results graphically by plotting estimates of sensitivities and
specificities in the receiver operating characteristic (ROC) space. We
also described metrics of pooled positive and negative likelihood
ratios. To allow an overview of IQCODE test accuracy we performed
a  further  analysis:  pooling  data  at  a  common  threshold  (3.3  or
closest), chosen to maximise the data available for inclusion.

The  presence  of  statistical  heterogeneity  was  assessed  by  visual
inspection of the included study results plotted in the ROC space
relative to the putative summary accuracy estimates.

Investigations of heterogeneity

Heterogeneity is expected in DTA reviews and we did not perform
formal analysis to quantify heterogeneity. 

The properties of a tool describe the behaviour of the instrument
under  particular  circumstances.  Thus,  for  our  assessment  of
potential  sources  of  heterogeneity  (where  data  allowed)  we
collected data to inform two broad pre-specified areas of interest.
These were:

• clinical  criteria  used  to  reach  dementia  diagnosis 

(for
example  ICD-10;  DSM-IV)  and  the  methodology  used  to  reach
the  dementia  diagnosis  (e.g.  individual  assessment;  group
(consensus) assessment);

Cochrane Database of Systematic Reviews

• technical  features  of  the  testing  strategy  (version  of  IQCODE
(language); numbers of items, that is short form of IQCODE or
long form).

Where  data  allowed  we  performed  pooled  analysis  with  these
factors as covariates and compared results of subgroups. We pre-
specified  that  we  would  present  data  from  the  traditional  (26
questions) and short form (16 questions) IQCODE separately.

Sensitivity analyses

Where appropriate (that is if not already explored in our analyses
of  heterogeneity)  and  as  data  allowed,  we  planned  to  explore
the  sensitivity  of  any  summary  accuracy  estimates  to  aspects  of
study quality guided by the anchoring statements developed in our
QUADAS-2 exercise. We pre-specified sensitivity analysis where we
planned to exclude studies of low quality (high likelihood of bias)
to determine if the results are influenced by inclusion of the lower
quality studies; and sensitivity analysis excluding studies that may
have unrepresentative populations.

R E S U L T S

Results of the search

Our search resulted in 16144 citations, of which 71 full text papers
were assessed for eligibility.

We  excluded  61  papers  (Figure  1).  Reasons  for  exclusion  were:
population not from a community (population) setting; no IQCODE
data  or  unsuitable  IQCODE  data;  small  numbers  of  included
participants;  no  clinical  diagnosis  of  dementia;  repeat  data  sets;
data not suitable for analysis (Characteristics of excluded studies).

Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the detection of dementia within community dwelling
populations (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

13

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Figure 1.   Study flow diagram.

Cochrane Database of Systematic Reviews

Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the detection of dementia within community dwelling
populations (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

14

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Figure 1.   (Continued)

Cochrane Database of Systematic Reviews

Eight studies that were identified required translation, these papers
were not suitable for this review but the data have been used for
reviews  of  IQCODE  in  other  healthcare  settings.  We  contacted  14
authors  to  provide  useable  data,  of  whom  10  responded.  These
data were not suitable for this (community setting) review but have
been used for other IQCODE analyses in this family of reviews (see
Acknowledgements).

This  review  included  10  studies  representing  11  data  sets  (n  =
2644 participants) (Summary of findings 1; Summary of findings 2;
Summary of findings 3).

Methodological quality of included studies

We  described  risk  of  bias  using  the  QUADAS  2  methodology
(Appendix 7).

No  study  was  graded  low  risk  of  bias  for  all  the  categories  of
QUADAS-2 (Figure 2; Figure 3). Areas of particular concern for bias
were around: participant sampling procedures (n = 2 papers graded
low risk, with few papers using a true consecutive sampling frame)
and application of index test (n = 1 paper graded low risk of bias,
with  most  papers  giving  insufficient  detail  on  how  the  IQCODE
was actually applied in practice). There were also concerns around
applicability, particularly concerning patient selection procedures
(n = 1 paper graded no concern, with few studies recruiting a cohort
representative of community-dwelling older adults).

Figure 2.   Risk of bias and applicability concerns graph: review authors' judgements about each domain presented
as percentages across included studies.

Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the detection of dementia within community dwelling
populations (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

15

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Figure 3.   Risk of bias and applicability concerns summary: review authors' judgements about each domain for each
included study.

We  described  reporting  quality  using  the  STARD  guidance
(Appendix  6).  One  paper  (Yamada  2011)  was  not  included  in  this
process as we had an expanded conference abstract or poster and
a  paper  describing  the  study  methodology  (Yamada  2008)  but  a
full  manuscript  with  IQCODE  data  had  not  yet  been  published.
There  were  limitations  in  reporting  across  all  included  papers
(Appendix 9). No paper included all the details recommended in the

STARD statement; particular areas of study reporting that could be
improved were: reporting of timing of the index test and reference
standard (n = 1 paper reported when the IQCODE was performed
in relation to the diagnostic evaluation); handling of indeterminate
results (n = 0 papers reported, for example, how incomplete IQCODE
questionnaires were handled); and describing variability between

Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the detection of dementia within community dwelling
populations (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

16

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

assessors (n = 2 papers reported data on interobserver variability
for index test or reference standard).

analysis (Jorm 1996 (psychiatry), favouring the data closest to the
expected population dementia prevalence.

Findings

The  individual  included  studies  have  been  described  in  detail
in  Characteristics  of  included  studies  and  Table  1;  we  have  also
presented tabulated data for test accuracy by covariate (Summary
of findings 2) and form of IQCODE threshold (Summary of findings
3).  The  total  number  of  participants  across  the  studies  was  2644
(range:  37  to  684),  of  whom  379  (14%)  had  a  clinical  dementia
diagnosis.  The  scope  of  the  included  studies  was  international;
included  data  sets  were  from  six  countries  (Australia,  Canada,
Japan, Spain, Sri Lanka and Thailand) (Appendix 10).

Certain papers contained more than one data set. For one paper
the data sets were independent (one urban, one rural) and so we
included these as separate entries (Morales 1997 (urban); Morales
1997 (rural)). One study had a single population assessed by two
independent assessors (one with neurology training and one with
psychiatry training). We used data from only one assessor for our

Ten different versions of IQCODE were used in the included studies
(Appendix  10)  and  eight  different  diagnostic  thresholds  (3.0,  3.2,
3.3, 3.4, 3.5, 3.6, 3.7, 4.0) were used to define a positive IQCODE. We
limited  our  analysis  to  the  validated  forms  of  IQCODE  that  are  in
common clinical use, that is the 26 and 16-item questionnaires.

Within the pre-specified thresholds chosen for analysis there was a
spread of sensitivity and specificity (sensitivity range: 44% to 92%;
specificity range: 55% to 96%).

Overview analysis - IQCODE using a 3.3 threshold or closest

Across 10 studies there were 11 data sets that contained relevant
data (n = 2644). Sensitivity was 0.80 (95% CI 0.75 to 0.85); specificity
0.85 (95% CI 0.78 to 0.90). The overall positive likelihood ratio was
5.27 (95% CI 3.7 to 7.5) and the negative likelihood ratio was 0.23
(95% CI 0.19 to 0.29).

The  summary  ROC  curve  describing  test  accuracy  across  the
included studies is presented in Figure 4.

Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the detection of dementia within community dwelling
populations (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

17

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Figure 4.   Summary ROC Plot, IQCODE using a 3.3 threshold score or nearest. The dark point is a summary point, the
broken line represents 95% CI

Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the detection of dementia within community dwelling
populations (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

18

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

IQCODE 3.3 threshold or closest - comparing 26 and 16-item
IQCODE

We  used  the  overview  data  set  to  examine  the  effect  of
heterogeneity  relating  to  IQCODE  format  (traditional  26-item  or
short form 16-item).

Analysis of the studies using the 26-item IQCODE (n = 7 data sets)
gave sensitivity of 0.80 (95% CI 0.73 to 0.85); specificity 0.86 (95%
CI 0.74 to 0.95). The overall positive likelihood ratio was 5.6 (95% CI
3.4 to 9.1) and the negative likelihood ratio was 0.24 (95% CI 0.18
to 0.31).

Cochrane Database of Systematic Reviews

Analysis of studies using the 16-item IQCODE (n = 5 data sets) gave
sensitivity of 0.80 (95% CI 0.74 to 0.85); specificity 0.82 (95% CI 0.70
to 0.89). The overall positive likelihood ratio was 4.2 (95% CI 2.6 to
6.8) and the negative likelihood ratio was 0.24 (95% CI 0.10 to 0.65).

Comparing  the  two  there  was  no  difference  in  accuracy,  with  a
relative  sensitivity  of  the  26-item  versus  16-item  IQCODE  of  1.00
(95%  CI  0.91  to  1.11)  and  relative  specificity  0.94  (95%  CI  0.82  to
1.09) (Figure 5).

Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the detection of dementia within community dwelling
populations (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

19

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Figure 5.   Summary ROC plot of IQCODE 3.3 threshold or nearest, comparing short form (16 item) and traditional
IQCODE.

As  there  was  no  difference  we  presented  further  data  as  the
combined (26 and 16-item IQCODE together) test accuracy.

(English language) with all translated IQCODE forms (non-English
language).

IQCODE 3.3 threshold or closest - comparing English and non-
English language IQCODE

We coded the language of IQCODE administration as a covariate.
Study  numbers  did  not  allow  analysis  by  individual  languages
and  so  we  compared  the  IQCODE  in  the  original  wording

Analysis of studies using English language IQCODE (n = 5 data sets)
gave sensitivity of 0.78 (95% CI 0.69 to 0.85); specificity 0.77 (95%
CI 0.63 to 0.86). The overall positive likelihood ratio was 6.7 (95% CI
4.6 to 9.7) and the negative likelihood ratio was 0.28 (95% CI 0.20
to 0.41).

Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the detection of dementia within community dwelling
populations (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

20

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis of studies using non-English language IQCODE (n = 7 data
sets) gave sensitivity 0.80 (95% CI 0.74 to 0.85); specificity 0.88 (95%
CI 0.82 to 0.92). The overall positive likelihood ratio was 6.7 (95% CI
4.6 to 9.7) and the negative likelihood ratio was 0.13 (95% CI 0.08
to 0.24).

Comparing  the  two  there  was  no  difference  in  accuracy,  with
a  relative  sensitivity  of  1.03  (95%  CI  0.91  to  1.16)  and  relative
specificity of 1.15 (95% CI 0.98 to 1.34) (Figure 6).

Figure 6.   Summary ROC Plot of pooled IQCODE data at a 3.3 threshold (or nearest value), with language as
covariate. The dark point is a summary point, the broken line represents 95% CI

As  there  was  no  significant  difference  between  groups  we
presented  the  data  (all  languages)  for  each  of  our  pre-specified
thresholds.

Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the detection of dementia within community dwelling
populations (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

21

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

IQCODE test accuracy at differing diagnostic thresholds

We  calculated  test  accuracy  at  our  pre-specified 
IQCODE
thresholds. We chose to present a summary ROC curve for those
analyses with greater than three included studies.

IQCODE  3.3  threshold:  there  were  six  data  sets*  (n  =  1232)  that
contained  relevant  data.  The  sensitivity  was  0.83  (95%  CI  0.74  to
0.90);  specificity  0.80  (95%  CI  0.70  to  0.88).  The  overall  positive
likelihood  ratio  was  4.25  (95%  CI  2.75  to  6.56)  and  the  negative
likelihood ratio was 0.21 (95% CI 0.14 to 0.32) (Figure 7).

Figure 7.   Summary ROC Plot of combined(16 and 26 item) IQCODE data using a 3.3 threshold score. The dark point is
a summary point, the broken line represents 95% CI

IQCODE  3.4  threshold:  there  were  three  data  sets*  (n  =  988)
that  contained  relevant  data.  The  sensitivity  was  0.84  (95%  CI
0.70  to  0.93);  specificity  0.80  (95%  CI  0.65  to  0.90).  The  overall
positive likelihood ratio was 4.42 (95% CI 2.47 to 7.90); the negative
likelihood ratio was 0.19 (95% CI 0.10 to 0.35).

IQCODE 3.5 threshold: there were three data sets* (n = 1144) that
contained relevant data. Sensitivity was 0.82 (95% CI 0.75 to 0.87);
specificity 0.84 (95% CI 0.80 to 0.88). The overall positive likelihood
ratio  was  5.09  (95%  CI  4.08  to  6.33);  the  negative  likelihood  ratio
0.22 (95% CI 0.16 to 0.29).

Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the detection of dementia within community dwelling
populations (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

22

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

IQCODE  3.6  threshold:  there  were  three  studies  (n  =  1215)  that
contained relevant data. Sensitivity was 0.78 (95% CI 0.68 to 0.86);
specificity  was  0.87  (95%  CI  0.71  to  0.95).  The  overall  positive
likelihood  ratio  was  6.00  (95%  CI  2.72  to  13.26);  the  negative
likelihood ratio was 0.25 (95% CI 0.18 to 0.34).

* Certain papers included more than one data set

Heterogeneity relating to dementia diagnosis

A quantitative analysis of the effect of dementia diagnosis criteria
(reference  standard)  was  not  possible  as  all  but  one  (Jorm
1996  (psychiatry)  of  the  studies  that  specified  the  approach  to
dementia  diagnosis  used  the  American  Psychiatric  Association
Diagnostic  and  Statistical  Manual  of  Mental  Disorders  (DSM)  to
define  the  dementia  state.  The  remaining  study  used  the  World
Health  Organization  (WHO)  International  Statistical  Classification
of Diseases and Related Health Problems (ICD) for diagnosis. This
study  also  compared  neurologists’  and  psychiatrists’  diagnoses
against  the  IQCODE  and  found  that  IQCODE  was  more  sensitive
compared  to  a  psychiatrist's  diagnosis  of  dementia  (Jorm  1996
(psychiatry).

A further original aim was to describe the accuracy of the IQCODE
for diagnosis of Alzheimer’s disease dementia. We were unable to
assess this based on the available data as only one study defined
specific dementia diagnoses (Law 1995); all other studies described
the accuracy of IQCODE for diagnosis of all cause dementia only.

Other sources of heterogeneity and sensitivity analyses

One  study  was  of  community-dwelling  stroke-survivors  (Srikanth
2006);  we  performed  a  sensitivity  analysis  by  removing  these
data  from  our  pooled  estimates.  We  found  little  difference  in
test  accuracy  when  this  study  was  removed  (at  a  3.3  threshold,
sensitivity 0.81, 95% CI 0.73 to 0.87; specificity 0.81, 95% CI 0.70 to
0.85).

We performed a sensitivity analysis removing studies with a 'young'
population. Not all studies provided data on the age of participants
and descriptive metrics differed across the papers (Table 2). Two
authors  (TJQ,  PF)  reviewed  the  ages  of  the  included  populations
and concluded that one study contained a 'younger' cohort likely
to meet our pre-specified arbitrary cut-off of more than 20% aged
less than 65 years (Senanorong 2001; see Table 2). This study also
had  an  unusually  high  prevalence  of  dementia  suggesting  that  a
case-control  methodology  was  employed,  although  this  was  not
explicitly stated in the paper. We performed a sensitivity analysis
excluding  this  study.  Test  accuracies  at  thresholds  of  3.4  and  3.5
were similar after exclusion of this study (sensitivity 0.82, 95% CI
0.72 to 0.89; specificity 0.79, 95% CI 0.66 to 0.89 at a 3.4 cut-point;
sensitivity 0.82, 95% CI 0.74 to 0.88; specificity 0.83, 95% CI 0.78 to
0.87 at a 3.5 cut-point).

Given the modest numbers of papers and the clinical heterogeneity
we  did  not  perform  any  further  sensitivity  analysis  by  QUADAS-2
metrics or other factors.

D I S C U S S I O N

Summary of main results

Cochrane Database of Systematic Reviews

Our results suggests that although the IQCODE has reasonable test
properties, for example the positive likelihood ratio of around 5 and
negative  likelihood  ratio  of  around  0.2  are  classically  interpreted
as  indicative  of  a  'moderately  good  test',  the  test  alone  may  not
be suited for dementia screening within community dwelling older
adults.

For  a  clinical  assessment  the  preferred  pattern  of  diagnostic  test
accuracy (DTA), optimising sensitivity versus optimising specificity,
will  vary  with  the  purpose  of  the  test.  The  utility  and  limitations
of  screening  all  community-dwelling  older  adults  for  cognitive
problems  is  a  topic  that  is  attracting  considerable  international
debate. Our data show that even for a 'good' initial assessment like
IQCODE,  at  a  population  level  the  number  of  false  positives  and
false negatives is still considerable. Applying our summary data to
a population such as the UK, where 9.2 million adults are aged over
65  and  6.6%  (435,600)  of  this  group  may  have  dementia,  we  see
that even modest problems in test accuracy can be associated with
considerable  numbers  of  false  diagnoses  or  false  reassurance  at
population level (using these population numbers and at sensitivity
of 0.80 / specificity of 0.84 we find false positive numbers of around
1314,660; false negative numbers of around 87,120). We appreciate
that in practice the use of such tests is more pragmatic, but we give
this example to illustrate the potential effects of IQCODE screening
at a population level.

Accepting that IQCODE is a reasonable initial test, albeit is perhaps
not sufficient as a single screening test, our pre-specified analyses
around  heterogeneity  were  designed  to  provide  guidance  on
optimal IQCODE administration with specific reference to form of
IQCODE; language of IQCODE and preferred test positive cut-point.

There  was  little  difference  in  sensitivity  across  the  predefined
diagnostic cut-points. We had expected a more pronounced 'trade-
off'  between  sensitivity  and  specificity  at  differing  thresholds.
Possible explanations are that the thresholds are too close together
to  see  differences  in  accuracy  between  neighbouring  cutoffs  or
that  any  differences  are  lost  in  between  study  heterogeneity.  We
can  conclude  that  at  the  IQCODE  values  commonly  described  in
research, there is little to choose between the thresholds. There was
a suggestion that sensitivity began to fall at cut-points above 3.5
and a trend towards improved specificity with increasing cut-point
from 3.3 to 3.6. It would seem intuitive that scores above and below
these  values  would  have  a  more  marked  difference  in  sensitivity
to specificity ratio. In certain situations, for example in dementia
screening where specificity may be preferred to avoid false positive
diagnosis, a cutoffs below 3.3 may be preferred. However, we found
few published studies describing thresholds less than 3.3 or greater
than 3.6 and so at present this hypothesis is speculative.

There were many differing forms of IQCODE application described
across  the  included  papers.  We  pre-specified  a  comparative
analysis  of  IQCODE  when  used  with  the  traditional  26  questions
and  a  short  form  with  16  questions.  As  the  tools  had  similar
accuracy we believe pooling data across these two IQCODE formats
was  valid.  There  were  insufficient  data  to  describe  accuracy  of
IQCODE assessments that did not use the standard 26 or 16 item
questionnaires  and  we  were  wary  of  describing  test  accuracy  of
unvalidated IQCODE based assessments.

We offer a synthesis of the published data describing the accuracy
of the IQCODE questionnaire tool for detection of dementia within
community-dwelling populations.

The  other  area  of  heterogeneity  in  IQCODE  application  was  for
language  of  administration.  There  were  insufficient  numbers  of
papers to allow a valid analysis of the effect of individual languages

Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the detection of dementia within community dwelling
populations (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

23

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

of  IQCODE,  however  summary  analysis  using  dichotomised
language  ('English'  or  'non-English')  as  a  covariate  suggested  no
significant  difference.  Although  not  reaching  significance,  there
was  a  trend  towards  differing  accuracy.  The  effect  was  not  as
expected with the non-English language IQCODE seemingly having
improved  accuracy.  However  differences  were  modest  and  it
seems  likely  that  some  of  these  difference  will  relate  to  differing
study methodologies and populations rather than the scale itself.
Nonetheless we should be mindful of potential language effects in
interpreting  the  pooled  analysis  and  future  studies  should  detail
the language(s) of administration of tests employed.

We restricted our analysis to the healthcare setting of "community
based  studies".  This  setting  and  terminology  was  chosen  prior
to  searching  and  review  of  the  literature.  Our  intention  was
to  assess  those  studies  where  participants  had  not  been
included  on  the  basis  of  cognitive  testing  or  symptoms  and  we
suspected  that  included  studies  would  have  a  population  level
assessment methodology. Across the literature describing IQCODE,
the  "community"  setting  proved  difficult  to  operationalize  and
included a number of differing population sampling methods and
study  types.  Certain  included  studies  could  be  criticised  for  not
conforming to usual definitions of unselected, community dwelling
older  adults  (for  example  one  study  was  of  ex-servicemen  only).
We included all community based studies if participants were not
selected  on  the  basis  of  a  factor  that  may  relate  to  dementia
or  cognitive  functioning.  One  study,  although  community  based,
included stroke survivors only. Clearly this group may differ from
a  non-stroke  population  and  we  explored  this  using  sensitivity
analyses. In fact, the test accuracy of IQCODE was similar comparing
stroke and non-stroke, albeit confidence intervals were necessarily
larger.

Even where papers seemed to have a population based sampling
frame,  the  prevalence  of  dementia  was  unexpectedly  high  and
we  must  be  cautious  in  our  interpretation  of  these  data.  For
unselected community assessment we would expect a prevalence
of  dementia  in  keeping  with  previous  population  estimates
(5%  of  adults  age  over  60  years;  6%  to  7%  of  adults  aged
over  65  years).  Only  one  of  our  included  papers  (Mackinnon
2003)  had  proportions  with  dementia  in  this  range.  One  study
had  a  younger  population  and  a  high  prevalence  of  dementia
suggesting a case-control methodology,albeit this was not explicit
in  the  manuscript,  again  we  explored  the  effect  of  removing  this
potentially  unrepresentative  study  with  sensitivity  analyses  and
found  little  difference  to  pooled  estimates  with  exclusion  of  the
paper.

In  many  of  the  included  studies  there  was  substantial  potential
for  bias  and  reporting  quality  was  suboptimal.  In  general,
authors  gave  sufficient  detail  and  were  robust  in  their  clinical
dementia assessment (reference standard); however methodology
and  reporting  of  patient  sampling  and  use  of  IQCODE  could  be
improved.

Assessment  of  quality  is  dependent  on  adequate  reporting
and  there  were  many  examples  where  QUADAS  scoring  was
complicated  by  insufficient  detail.  One  example  is  the  blinding
of  dementia  assessors  to  IQCODE  data,  particularly  as  dementia
diagnosis 
from
informants. We hope that the proposed dementia specific reporting
guidance of STARDdem may improve quality in future studies that
use dementia as reference standard.

is  often  partly  predicated  on 

information 

Cochrane Database of Systematic Reviews

Strengths and weaknesses of the review

The  strength  of  this  review  was  its  focused  study  question  and
setting. This review was limited to studies of community dwelling
adults.  While  this  approach  avoids  heterogeneity  that  may  be
introduced  by  test  'setting'  it  does  limit  applicability  to  other
settings and we should not extrapolate the data presented in this
review to hospital or primary care populations. Reviews of the test
accuracy  of  IQCODE  in  other  settings  and  of  the  test  accuracy  of
other direct and informant tests are planned as separate Cochrane
reviews.

We  performed  a  comprehensive  and  sensitive 
literature
search,  encompassing  cross-disciplinary  electronic  databases
and  test  accuracy  specific  resources.  Our  primary  search  was
complemented by contact with other authors working in the field
and we are grateful for all the helpful responses we received. We did
not limit by language of paper and this proved to be important as
studies of IQCODE were international and several papers required
translation.  An  unexpected  finding  was  the  modest  numbers  of
studies  describing  IQCODE  accuracy  in  community  settings  from
United Kingdom and North America.

Due  to  the  modest  numbers  of  papers,  we  pooled  data  for
our  summary  analysis  across  various  forms  of  IQCODE.  Our
comparative analysis would suggest that 16 and 26 item IQCODE
have  similar  test  accuracy,  however  language  of  administration
may influence properties and as a result our summary data must be
interpreted with some caution.

We  endeavoured  to  be  as  robust  as  possible  in  our  assessment
of included studies. Our approach to risk of bias assessment was
informed by a short life working group that met to define relevant
and  workable  anchoring  statements  and  definitions  of  criteria
(Appendix 8). As we felt that assessment of quality should include
a  measure  of  quality  of  reporting  we  also  assessed  the  included
papers using the STARD approach (Appendix 6).

Important  clinical  and  demographic  details  that  could  impact
on  the  interpretation  of  our  IQCODE  data  were  not  consistently
reported  and  we  could  not  describe  the  effect  of  factors  such  as
nature of the informant and severity of dementia. For translating
test  accuracy  studies  to  clinical  practice,  an  approach  that
describes  numbers  who  could  not  be  tested  with  index  and
reference  standard  is  often  useful  (i.e.  an  intention  to  diagnose
approach with a two by three or three by three table; rather than the
standard two by two table) (Schuetz 2012). We did not collect data
in this format and at present we do not have techniques to allow
pooling of such data.

We  await  the  results  of  ongoing  systematic  reviews  and  meta-
analyses of other dementia assessment strategies (many of which
are  being  completed  by  the  Cochrane  Dementia  and  Cognitive
Improvememt Group) before we can begin to compare assessments
and  suggest  the  optimal  tests  for  a  particular  patient  group  or
clinical indication.

Applicability of findings to the review question

We found studies relevant to our focused study question and were
able  to  give  summary  estimates  for  certain  of  our  pre-specified
co-variates  of  interest..  Our  primary  objective  was  to  determine
the  diagnostic  accuracy  of  the  informant  based  questionnaire
IQCODE,  for  detection  of  all  cause  (undifferentiated)  dementia  in

Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the detection of dementia within community dwelling
populations (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

24

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

community-dwelling  adults  and  we  provide  summary  data  that
hopefully  will  help  clinicians  and  policy  makers  understand  the
properties of IQCODE as an initial assessment in this setting.

A  priori  we  had  defined  a  number  of  subgroup  and  sensitivity
analyses, the limited number of included papers precluded many
of  these  analyses  and  we  have  not  definitively  answered  our
secondary  questions  of  describing  the  effect  of  age  or  dementia
diagnosis on test accuracy metrics. Further potential heterogeneity
will be introduced by the "stage"/severity of dementia at time of
diagnosis,  as  diagnosis  will  be  easier  in  advanced  disease  than
in  early  disease.  No  included  studies  gave  data  on  severity  of
diagnosis that would allow us to describe this effect and so based
on  available  data  we  can  make  no  specific  comment  on  use  of
IQCODE in, for example, early stage dementia.

the  analysis  we  had  conceptualised 

When  planning 
the
"community"  setting  as  being  closest  to  unselected,  population
screening. Most of the included papers, while fulfilling our criteria
for  "community",  still  described  selected  populations.  It  may  be
that this is of only minor consequence, as test accuracy of IQCODE
was  similar  even  when  comparing  highly  selected  groups  (for
example stroke survivors) to the pooled result.

A U T H O R S '   C O N C L U S I O N S

Implications for practice

Accepting the limitations of included studies and the potential for
baises, results were fairly consistent across the studies and allow
us  to  give  some  guidance  on  the  use  of  IQCODE.  Published  data
suggest that for initial assessment of dementia in older adults the
IQCODE  with  cut-points  of  3.3  to  3.6  could  be  used,  however  as
a single assessment tool IQCODE properties may not be suited to
population level screening. We extrapolated the IQCODE summary
accuracy data to a United Kingdom context as exemplar and can see
that using IQCODE exclusively will lead to substantial false positive
diagnosis. Given the public perception of dementia, it is arguable
that the distress caused by assigning a dementia label to a person
without the disease is greater than the potential harm of initially
missing dementia on screening. These are important concepts that
need  to  be  considered  if  large  scale  cognitive  screening  is  to  be
introduced.

The  choice  of  a  screening  tool  or  triage  tool  for  cognitive
assessment will not only be driven by test accuracy. Strengths of
the  IQCODE  from  a  clinician  or  healthcare  perspective  are  that  it
is copyright free; available in many languages; and relatively quick
and  easy  to  complete.  In  general,  informant-based  assessments
that do not rely on direct patient testing can capture change over
time  and  are  less  prone  to  social-cultural  biases  (Jorm  2000A;
Larner 2013). These are all factors that make IQCODE attractive as
an initial assessment tool and explain why it is popular in its clinical
and research use.

Our analyses of heterogeneity suggest that 26 and 16-item IQCODE
have similar test accuracy. It would seem sensible to recommend
the short version of IQCODE as administration time or burden is less
with  comparable  accuracy.  Other  short  form  versions  of  IQCODE
have been described, at present there are insufficient data available
to recommend use of these other modified IQCODE formats.

Cochrane Database of Systematic Reviews

There was a trend, albeit not reaching significance, to suggest that
the language of administration may impact on IQCODE accuracy.
Our findings do not imply that certain languages of assessment are
more or less accurate. The safest interpretation of these data is as a
reminder that translating IQCODE items to other languages needs
to be sensitive to idioms and cultural nuances. We would encourage
assessors using a non-English language IQCODE to ensure that any
translation and validation process has been suitably robust.

As  a  single  test  review,  our  data  do  not  allow  us  to  comment  on
how  the  IQCODE  performs  in  relation  to  other  tests.  Given  the
large number of assessment tools potentially available, this is the
question that may be of most interest to clinicians. In many papers
and in clinical practice, the information from IQCODE is often used
in  tandem  with  a  direct  patient  cognitive  assessment  tool  such
as MMSE. While combining instruments is intuitively attractive, at
present we do not have a systematic review of the properties of this
approach.

Implications for research

Our pooled analysis gives a large test population and the associated
estimates of diagnostic accuracy are reasonably robust. However,
we still encourage further study of the properties of IQCODE. As an
example,  despite  our  focused  study  question  around  community
setting, the included studies in our review were largely not typical
of  an  unselected,  older  adult  population.  The  ideal  study  would
involve  stratified  sampling  and  testing  based,  for  example,  on
census  data,  such  approaches  have  been  used  in  seminal  work
describing the epidemiology of dementia (Ferri 2005).

IQCODE test accuracy was maintained comparing 26 and 16-item
formats.  IQCODE  versions  with  even  fewer  than  16  items  have
been  described,  although  numbers  were  too  small  for  pooled
analysis  in  this  review.  In  practice  a  brief  assessment  tool  is  an
attractive  option  if  diagnostic  accuracy  can  be  maintained.  We
would recommend further study of shortened (less than 16-item)
IQCODE properties.

Our  review  had  a  deliberately  focused  agenda  and  our  data  do
not allow us to extrapolate the diagnostic properties of IQCODE to
other healthcare settings. We recognise that dementia assessment
with  additional  informant  interview  is  common  in  primary  care
and  hospital  settings  and  reviews  of  the  IQCODE  when  used  in
these settings are now required. We have alluded to the need for
comparative studies of various tools used alone or in combination.
The ongoing body of work by the Cochrane group describing the
test accuracy of commonly used direct and indirect tests will offer
a substrate for future indirect comparative meta-analysis.

Our assessments of reporting quality and risk of bias are concerning
but  in  keeping  with  results  from  other  areas  of  dementia
research. We urge dementia researchers to work towards improved
consistency  in  both  methodology  and  reporting  to  assist  future
reviews of the diagnostic accuracy of tests. The use of dementia-
specific guidance such as the proposed STARDdem initiative may
assist future trialists.

A C K N O W L E D G E M E N T S

We thank the following researchers who assisted with translation:

Salvador Fudio, EMM van de Kamp - van de Glind, Anja Hayen.

Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the detection of dementia within community dwelling
populations (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

25

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

We thank the following researchers who responded to requests for
original data:

Dr D Salmon, Dr S Sikkes, Dr G Potter, Dr M Razavi, Prof H Henon, Dr
JFM de Jonghe, Dr V Isella, Dr AJ Larner, Dr B Rovner, Dr M Krogseth.

We thank Dr Y Takwoingi for assistance with the statistical analysis.

Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the detection of dementia within community dwelling
populations (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

26

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

R E F E R E N C E S

References to studies included in this review

Jorm 1994 {published data only}

Jorm AF. A short form of the Informant Questionnaire on
Cognitive Decline in the Elderly (IQCODE): development and
cross validation. Psychological Medicine 1994;24:145-53.

Jorm 1996 (psychiatry) {published data only}

Jorm AF, Christensen H, Henderson AS, Jacomb PA, Korten AE,
Mackinnon A. Informant ratings of cognitive decline of elderly
people relationship to longitudinal change on cognitive tests.
Age and Ageing 1996;25:125-9.

Kathriarachi 2001 {published and unpublished data}

Kathriarachchi ST, Sivayogan S, Jayaratna SD, Dharmasena SR.
Comparison of three instruments used in the assessment
of dementia in Sri Lanka. Indian Journal of Psychiatry
2005;47:109-12.

Law 1995 {published and unpublished data}

Law S, Wolfson C. Validation of a French version of an informant
based questionnaire as a screening test for Alzheimer's disease.
British Journal of Psychiatry 1995;167:541-4.

Mackinnon 2003 {published data only}

Mackinnon A, Khalilian A, Jorm AF, Korten AE, Christensen H,
Mulligan R. Improving screening accuracy for dementia in
a community sample by augmenting cognitive testing with
informant report. Journal of Clinical Epidemiology 2003;56:358–
66.

Morales 1995 {published and unpublished data}

Morales JM, Gonzalez-Montalvo JI, Bermejo F, Del-Ser T. The
screening of mild dementia with a shortened Spanish version of
the Informant Questionnaire on Cognitive Decline in the Elderly.
Alzheimer's Disease and Associated Disorders 1995;9:105-11.

Morales 1997 (rural) {published and unpublished data}

Morales JM, Bermejo F, Romero M, Del-Ser T. Screening
of dementia in community dwelling elderly through
informant report. International Journal of Geriatric Psychiatry
1997;12:808-16. [these are data from independent rural cohort]

impairments and dementia after first ever stroke. International
Psychogeriatrics 2006;18:295-305.

Yamada 2011 {published and unpublished data}

Mimori Y, Miyachi T, Ohshita T, Nakamura S, Yamada M, Sasaki H,
Suzuki G. Cognitive decline and detection of dementia among
the Japanese population. Anlaysis with the CASI and IQCODE.
In: conference proceedings (poster). 2011.

References to studies excluded from this review

Abreu 2008 {published data only}

Abreu ID, Nunes PV, Diniz BS, Forlenza OV. Combining functional
scales and cognitive tests in screening for mild cognitive
impairment at a university based memory clinic in Brazil.
Revista Brasileira de Pisquiatria 2008;30:346-9.

Butt 2008 {published data only}

Butt Z. Sensitivity of the IQCODE an application of item
response theory. Aging, Neuropsychology and Cognition
2008;15:642-55.

Cherbuin 2008 {published data only}

Cherbuin N, Anstey KJ, Lipnicki DM. Screening for dementia
a review of self and informant assessment instruments.
International Psychogeriatrics 2008;20:431-58.

de Jonge 1997 {published data only}

De Jonghe JFM. Differentiating between demented and
psychiatric patients with the dutch version of IQCODE.
International Journal of Geriatric Psychiatry 1997;12:462-5.

Dekkers 2009 {published data only}

Dekkers M, Joosten-Weyn Banningh EW, Eling PA. Awareness
in patients with mild cognitive impairment. Tijdschrift voor
Gerontologie en Geriatrie 2009;40:17-23.

Diefeldt 2007b {published data only}

Diesfeldt HFA. Informant based measures may over estimate
cognitive impairment in elderly patients. International Journal
of Geriatric Psychiatry 2007;22:1166-70.

Morales 1997 (urban) {published and unpublished data}

Diesfeldt 2007 {published data only}

Morales JM, Bermejo F, Romero M, Del-Ser T. Screening
of dementia in community dwelling elderly through
informant report. International Journal of Geriatric Psychiatry
1997;12:808-16.

Senanorong 2001 {published and unpublished data}

Senanarong V, Assavisaraporn S, Sivasiriyanonds N,
Printarakul T, Jamjumrus S, Udompunthurunk S, Poungvarin N.
The IQCODE an alternative screening test for dementia for low
educated Thai elderly. Journal of the Medical Association of
Thailand 2001;84:648-55.

Srikanth 2006 {published data only}

Srikanth V, Thrift AG, Fryer JL, Saling MM. The validity of brief
screening cognitive assessments in the diagnosis of cognitive

Diesfeldt HFA. Discrepancies between IQCODE and cognitive
test performance. Tijdschrift voor Gerontologie en Geriatrie
2007;38:199-209.

Ehrensperger 2010 {published data only}

Enrensperger MM, Berres M, Taylor KI, Monsch AU. Screening
properties of the German IQCODE with a two year time
frame in MCI and early Alzheimer's disease. International
Psychogeriatrics 2010;22:91-100.

Farias 2002 {published data only}

Farias ST, Mungas D, Reed B, Haan MN, Jagust WJ. Everyday
imaging in relation to cognitive functioning and neuroimaging
in community dwelling Hispanic and non Hispanic older

Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the detection of dementia within community dwelling
populations (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

27

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

adults. Journal of the International Neuropsychological Society
2004;10:342-54.

Finneli (abstract) {published data only}

Finelli L, Kunze U, Gautier A, Gomez-Mancilla B, Monsch AU.
Algorithms to retrospectively diagnose mild cognitive
impairment and dementia in a longitudinal study of ageing and
dementia. In: abstract ICAD. 2009.

Fuh 1995 {published data only}

Fuh JL, Teng EL, Lin KN, Larson EB, Wang SJ, Liu CY et al. The
Informant Questionnaire on Cognitive Dcline in the Elderly as
a screening tool for dementia for a predominantly illiterate
Chinese population. Neurology 1995;45:92-6.

Garcia 2002 {published data only}

Forcano Garcia M, Perlado Ortiz de Pinedo F. Cognitive
deterioration: use of the short version of the Informant Test
(IQCODE) in the geriatrics consultations. Revista Espanola de
Geriatria y Gerontolgia 2002;37:81-5.

Jorm 1989 {published data only}

Jjorm AF, Scott R, Jacomb PA. Assessment of cognitive decline
in dementia by informant questionnaire. International Journal
of Geriatric Psychiatry 1989;4:35-9.

Jorm 1989b {published data only}

Jorm AF, Jacomb PA. The IQCODE; sociodemographic
correlates, reliability, validity and some norms. Psychological
Medicine 1989;19:1015-22.

Jorm 1991 {published data only}

Jorm AF, Scott R, Cullen JS, MacKinnon AJ. Performance of the
IQCODE as a screening test for dementia. Psychological Medicine
1991;21:785-90.

Jorm 1996 (Age and Ageing {published data only}

Jorm AF, Christensen H, Henderson AS, Jacomb PA, Korten AE,
Mackinnon A. Informant ratings of cognitive decline of elderly
people relationships to longitudinal change on cognitive tests.
Age and Ageing 1996;25:125-9.

Goncalves 2011 {published data only}

Jorm 1997 {published data only}

Goncalves DC, Arnold E, Appadurai K, Byrne GJ. Case finding
in dementia: comparative utility of three brief instruments
in the memory clinic setting. International Psychogeriatrics
2011;23:788-96.

Jorm AF. Methods of screening for dementia: a meta-analysis
of studies comparing an informant interview with a brief
cognitive test. Alzheimers Disease and Associated Disorders
1997;11:158-62.

Hancock 2009 {published data only}

Jorm 2000 {published data only}

Hancock P, Larner AJ. Diagnostic utility of the IQCODE and its
combination with ACE-R in a memory clinic based population.
International Psychogeriatrics 2009;21:526-30.

Jorm AF, Christensen H, Korten AE, Jacomb PA, Henderson AS.
Informant ratings of cognitive decline in old age. Psychological
Medicine 2000;30:981-5.

Harwood 1997 {published data only}

Harwood DMJ, Hope T, Jacoby R. Cognitive impairment in
medical inpatients - screening for dementia is history better
than mental state. Age and Ageing 1997;26:31-5.

Jorm 2003 {published data only}

Jorm AF. The value of informant reports for assessment and
prediction of dementia. Journal of the American Geriatrics
Association 2003;51:881-2.

Hayden 2003 {published data only}

Jorm 2004 {published data only}

Hayden KM, Khachaturian AS, Tschanz JT, Corcoran C,
Nortond M, Breitner JCS. Characteristics of a two-stage
screen for incident dementia. Journal of Clinical Epidemiology
2003;56:1038-45.

Henon 2001 {published data only}

Henon H, Durieu I, Guerouaou D, Lebert F, Pasquier F, Leys D.
Poststroke dementia incidence and relationship to pre-stroke
cognitive decline. Neurology 2001;57:1216-22.

Isella 2002 {published data only}

Isella V, Villa ML, Frattola L, Appollonio I. Screening cognitive
decline in dementia preliminary data on the Italian version of
the IQCODE. Neurological Sciences 2002;23:s79-s80.

Isella 2006 {published data only}

Isalla V, Villa L, Russo A, Regazzoni R, Ferrarese C, Appollonio IM.
Discriminitive and predictive power of an informant report in
mild cognitive impairment. Journal of Neurology, Neurosurgery,
and Psychiatry 2006;77:166-71.

Jorm AF. The IQCODE: a review. International Psychogeriatrics
2004;16:275-93.

Khachaturian 2000 {published data only}

Khachaturian AS, Gallo JJ, Breitner JC. Performance
characteristics of a two stage dementia screen in a population
sample. Journal of Clinical Epidemiology 2000;53:531-40.

Knaefelc 2003 {published data only}

Knafelc R, Giudice DL, Harrigan S, Cook R, Flicker L,
Mackinnon A, Ames D. The combination of cognitive testing and
an informant questionnaire in screening for dementia. Age and
Ageing 2003;32:541-547.

Krogseth 2011 {published data only}

Krogseth M, Wyller TB, Engedal K, Juliebo V. Delirium is an
important predictor of incident dementia among elderly hip
fracture patients. Dementia and Geriatric Cognitive Disorders
2011;31:63-70.

Larner 2010 {published data only}

Larner AJ. Can IQCODE differentiate Alzheimer's disease from
frontotemporal dementia. Age and Ageing 2010;39:392-4.

Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the detection of dementia within community dwelling
populations (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

28

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Larner 2013 {published data only}

Cherbuin N, Jorm AF. Chapter 8. The Informant Questionnaire
for Cognitive Decline in the Elderly. In: Larner AJ, editors(s).
Cognitive Screening Instruments. London: Springer-Verlag,
2013:166-79.

Li 2012 {published data only}

Li F, Jia XF, Jia J. The Informant Questionnaire on Cognitive
Decline in the Elderly individuals in screening mild cognitive
impairment with or without functional impairment. Journal
Geriatric Psychiatry and Neurology 2012;25:227-32.

Louis 1999 {published data only}

Louis B, Harwood D, Hope T, Jacoby R. Can an informant
questionnaire be used to predict the development of dementia
in medical inpatients. International Journal of Geriatric
Psychiatry 1999;14:941-5.

Mackinnon 1998 {published data only}

Mackinnon A, Mulligan R. Combining cognitive testing and
informant report to increase accuracy in screening for
dementia. American Journal of Psychiatry 1998;155:1529-35.

Mimori (abstract) {published data only}

Mimori Y. Cognitive decline and detection of dementia among
the Japanese population analysis with CASI and IQCODE. In:
abstract. 2010:s451.

Morales-Gonzalez 1992 {published data only}

Morales-Gonzalez JM, Gonzalez-Montalvo JL, De Ser Quijano T,
Bermejo Pareja F. Validation of the S-IQCODE [Original paper in
Spanish]. Archivos de Neurobiologiá (Madrid) 1992;55:262-6.

Mulligan 1996 {published data only}

Mulligan R, Mackinnon A, Jorm A, Giannakopoulos P, Michel J. A
comparison of alternative methods of screening for dementia in
clinical settings. Archives of Neurology 1996;53:532-6.

Narasimhalu 2008 {published data only}

Narasimhalu K, Lee J, Auchus AP, Chen CPLH. Improving
detection of dementia in Asian patients with low education
combining the MMSE and the IQCODE. Dementia and Geriatric
Cognitive Disorders 2008;25:17-22.

Cochrane Database of Systematic Reviews

in African Americans and whites. Alzheimer's & Dementia
2009;5:445-53.

Razavi 2011 {published and unpublished data}

Razavi M, Margrett J, Oakland A, Martin P. Comparison of two
informant questionnaire screening tools for dementia. In:
abstract. 2011.

Ritchie 1992 {published data only}

Ritchie K, Fuhrer R. A comparative study of the performance
of screening tests for senile dementia using receiver operating
characteristics analysis. Journal of Clinical Epidemiology
1992;45:627-37.

Rodriguez-Molinero 2010 {published data only}

Rodriguez-Molinero A, Lopez-Dieguez M, Medina IP,
Tabuenca AI, de la Cruz JJ, Banegas JR. Cognitive assessment of
elderly patients in the emergency department. Revista Espanola
de Geriatria y Gerontolgia 2010;45:183-8.

Rovner 2012 {published data only}

Rovner BW, Casten RJ, Arenson C, Salzman B, Kornsey EB.
Racial differences in the recognition of cognitive dysfunction
in older persons. Alzheimer's Disease and Associated Disorders
2012;26:44-9.

Sanchez 2009 {published data only}

dos Santos Sanchez MA, Lourenco RA. IQCODE cross cultural
adaptation for use in Brazil. Cadernos de Saude Publica
2009;25:1455-65.

Schofield 2006 {published data only}

Schoffield PW. Discrepancies in cognitive history from patient
and informant in relation to cognitive function. Research and
Practice in Alzheimer's Disease 2006;11:328-31.

Sikkes 2010 {published data only}

Sikkes SAM, van den Berg MT, Knol DL, de-Lange-de Klerk ESM,
Scheltens P, Uitdehaag BMJ et al. How useful is IQCODE for
discriminating between Alzheimer's disease, mild cognitive
impairment and subjective memory complaints? Dementia and
Geriatric Cognitive Disorders. 2010;30:411-6.

Siri 2006 {published data only}

Ozel-kizel 2010 {published data only}

Ozel-Kizel ET, Turan ED, Yilmaz E, Cangoz B, Uluc S. Discriminant
validity and reliability of the Turkish version of the IQCODE.
Archives of Clinical Neuropsychology 2010;25:139-45.

Siri S, Okanurak K, Chansirikanjana S, Kitiyaporn D, Jorm AF.
Modified IQCODE as a screening test for dementia for Thai
elderly. Southeast Asian Journal Tropical Medicine and Public
Health 2006;37:587-94.

Peroco 2009 {published data only}

Perroco TR, Zevallos Bustamente SE, del Pilar Q, Moreno M,
Hototian SR, Lopes MA et al. Performance of Brazilian long
and short IQCODE on the screening of dementia in elderly
people with low education. International Psychogeriatrics
2009;21:531-8.

Potter 2009 {published data only}

Potter GG, Plassman BL, Burke JR, Kabeto MU, Langa KM,
Llewellyn DJ et al. Cognitive performance and informant
reports in the diagnosis of cognitive impairment and dementia

Starr 2000 {published data only}

Starr JM, Nicolson C, Anderson K, Dennis MS, Deary IJ.
Correlates of informant rated cognitive decline after stroke.
Cerebrovsacular Diseases 2000;10:214-20.

Tang 2003 {published data only}

Tang WK, Sandra SMC, Chiu HFK, Wong KS, Kwok TCY, Mok V,
Ungvari GS. Can IQCODE detect post stroke dementia.
International Journal of Geriatric Psychiatry 2003;18:706-10.

Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the detection of dementia within community dwelling
populations (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

29

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Thomas 1994 {published data only}

Thomas LD, Gonzales MF, Chamberlain A, Beyreuther K,
Masters CL, Flicker L. Comparison of clinical state retrospective
informant interview and the neuropathological diagnosis of
Alzheimer's disease. International Journal of Geriatric Psychiatry
1994;9:233-6.

Tokuhara 2006 {published data only}

Tokuhara KG, Valcour VG, Masaki KH, Blanchette PL. Utility of
the IQCODE for dementia in a Japanese American population.
Hawai'i Medical Journal 2006;65:72-5.

Wierderholt 1999 {published data only}

Wiederholt WC, Galasko D, Salmon DP. Utility of CASI and
IQCODE as screening instruments for dementia in natives of
Guam. In: abstract (World Congress of Neurology). 1997.

Wolfe 2009 {published data only}

Wolf SA, Kubatschek K, Henry M, Harth S, Edbert AD,
Wallesch CW. Informant report of cognitive changes in the
elderly. A first evaluation of the German version of the IQCODE.
Nervenartz 2009;10:1178-80.

Zevallos-Bustamente 2003 {published data only}

Zevallos Bustamante SE, Bottino CMC, Lopes MA, Dionísio
Azevedo D, Hototatian SR, Litvoc J, Filho JW. Combined
instruments on the evaluation of dementia in the elderly
preliminary results. Arquivos de Neuro-Psiquiatria
2003;61:601-6.

Zhang 2003 {published data only}

Zhang XQ, Zhou JS, Wang LD, Meng C, Chen B. Memory
complaints in the clinical diagnosis of dementia. Chinese
Journal of Clinical Rehabilitation 2003;7:4254-5.

Zhou 2002 {published data only}

Zhou JS, Zhang XQ, Wang L. Telephone questionnaire a new
method for screening dementia. Chinese Journal of Clinical
Rehabilitation 2002;6:3166-7.

Zhou 2003 {published data only}

Zhou J, Xinqing Z, Wang L, Meng C, Chu C, Chen B. Orientation
memory concentration test and short IQCODE in the elderly
screen dementia by telephone. Chinese Journal of Clinical
Rehabilitation 2003;7:1529-31.

Zhou 2004 {published data only}

Zhou JS, Zhang XQ, Wang L. Telephone IQCODE for dementia.
In: abstract. 2004.

Additional references

Birks 2006

Birks J. Cholinesterase inhibitors for Alzheimer's disease.
Cochrane Database of Systematic Reviews 2006;1:CD005593.

Bossuyt 2003

Bossuyt PM, Reitsma JB, Bruns DE Gatsonis CA, Glasziou PP,
Irwig LM et al. Towards complete and accurate reporting

Cochrane Database of Systematic Reviews

of studies of diagnostic accuracy: the STARD initiative. BMJ
2003;326:41-4.

Boustani 2003

Boustani M, Peterson B, Hanson L, Harris R, Lohr KN. Screening
for dementia in primary care: a summary of the evidence for the
US Preventative Services Task Force. Annals of Internal Medicine
2003;138:927-37.

Brodaty 2002

Brodaty H. The GPCOG a new screening test for dementia
designed for general practice. Journal of the American Geriatrics
Society 2002;50:530-4.

Brunet 2012

Brunet MD, McCartney M, Heath I, Tomlinson J, Cosgrove J,
Deveson P et al. Open letter to the Prime Minister and Chief
Medical Officer for England. There is no evidence base for
proposed dementia screening. BMJ 2012;345:e8588.

Chodosh 2004

Chodosh J, Petitti DB, Elliott M, Hays RD, Crooks VC, Reuben DB
et al. Physician recognition of cognitive impairment: evaluating
the need for improvement. Journal of the American Geriatrics
Society 2004;52:1051-9.

Clare 2003

Clare L, Woods B. Cognitive rehabilitation and cognitive training
for early-stage Alzheimer's disease and vascular dementia.
Cochrane Database of Systematic Reviews 2003;4:CD003260.

Cordell 2013

Cordell CB, Borson B, Boustani M, Chodosh J, Reuben D,
Verghese J et al, Medicare Detection of Cognitive Impairment
Group. Alzheimer's Associaton recommendations for
operationalizing the detection of cognitive impairment during
the Medicare Annual Wellness Visit in a primary care setting.
Alzheimer’s & Dementia 2013;9:141-50.

Cordoliani-Mackowiak 2003

Cordoliani-Mackowiak MA, Henon H, Pruvo JP, Pasquier F,
Leys D. Poststroke dementia influence of hippocampal atrophy.
Archives of Neurology 2003;60:585-90.

Cullen 2007

Cullen B, O’Neill B, Evans JJ, Coen RF, Lawlor BA. A review of
screening tests for cognitive impairment. Journal of Neurology,
Neurosurgery, and Psychiatry 2007;78:790–9.

Erkinjuntti 2000

Erkinjuntti T, Inzitari D, Pantoni L. Research criteria for
subcortical vascular dementia in clinical trials. Journal of Neural
Transmission. Supplementa 2000;59:23–30.

Ferri 2005

Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M
et al, Alzheimer's Disease International. Global prevalence of
dementia: a Delphi consensus study. Lancet 2005;366:2112-7.

Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the detection of dementia within community dwelling
populations (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

30

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Folstein 1975

McKhann 2001

Folstein MF, Folstein SE, McHugh PR. Minimental state: a
practical method for grading the cognitive state of patients for
the clinician. Journal of Psychiatric Research 1975;12:189–98.

Galvin 2005

Galvin JE. A brief informant interview to detect dementia.
Neurology 2005;65:559-64.

Greenhalgh 2005

Greenhalgh T, Peacock R. Effectiveness and efficiency of search
methods in systematic reviews of complex evidence: audit of
primary sources. BMJ 2005;331:1064-5.

Hebert 2003

Hebert LE, Scherr PA, Bienas JL, Bennett DA, Evans DA.
Alzheimers disease in the US population: prevalence estimates
using the 2000 census. Archives of Neurology 2003;60:1119-22.

Holsinger 2007

Holsinger T, Deveau J, Boustani M, Willimas JW. Does this
patient have dementia. JAMA 2007;21:2391-404.

Jorm 1988

Jorm AF, Korten AE. Assessment of cognitive decline in the
elderly by informant interview. British Journal of Psychiatry
1988;152:209–13.

Jorm 1989A

Jorm AF, Jacomb PA. The informant questionnaire on cognitive
decline in the elderly (IQCODE) sociodemographic correlates;
reliability; validity and some norms. Psychological Medicine
1989;19:1015-22.

Jorm 2000A

Jorm AF, Christensen H, Henderson AS, Jacomb PA, Korten AE,
Mackinnon A. Informant ratings of cognitive decline in old age:
validation against change on cognitive tests over 7-8 years.
Psychological Medicine 2000;30:981-5.

Matthews 2013

Matthews FE, Arthur A, Barnes LE, Bond J, Jagger C, Robinson L,
Brayne C, Medical Research Council Cognitive Function and
Ageing Collaboration. A two-decade comparison of prevalence
of dementia in individuals aged 65 years and older from three
geographical areas of England: results of the Cognitive Function
and Ageing Study I and II. Lancet 2013;382(9902):1405-12.

McKhann GM, Albert MS, Grossman M, Miller B, Dickson D,
Trojanowski JQ, Work Group on Frontotemporal Dementia
and PIck’s Disease. Clinical and pathological diagnosis of
frontotemporal dementia: report of the Work Group on
Frontotemporal Dementia and Pick's Disease. Archives of
Neurology 2001;58:1803-9.

McKhann 2011

McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr,
Kawas CH et al. The diagnosis of dementia due to Alzheimer’s
disease:recommendations from the National Institute on Aging
and the Alzheimer’s Association workgroup. Alzheimer's &
Dementia 2011;7(3):263-9.

McShane 2006

McShane R, Areosa Sastre A, Minakaran N. Memantine
for dementia. Cochrane Database of Systematic Reviews
2006;2:CD003154.

Noel-Storr 2012

Noel-Storr AH, Flicker L, Ritchie CW, Nquyen GH, Gupta T, Wood
P et al. Systematic review of the body of evidence for the use of
biomarkers in diagnosis of dementia. Alzheimer's & Dementia
2013;9(3):e96-e105. doi:10.1016/j.jalz.2012.01.014.

Reitsma 2005

Reitsma JB, Glas AS, Rutjes AW, Scholten RJ, Bossuyt PM,
Zwinderman AH. Bivariate analysis of sensitivity and specificity
produces informative summary measures in diagnostic reviews.
Journal of Clinical Epidemiology 2005;58:982-90.

RevMan 2011 [Computer program]

Review Manager (RevMan) 5.1. The Nordic Cochrane Centre, The
Cochrane Collaboration. Copenhagan: The Nordic Cochrane
Centre, 2011.

Rockwood 1998

Rockwood K. Retrospective diagnosis of dementia using an
informant interview based on the Brief Cgnitive Rating Scale.
International Psychogeriatrics 1998;10:53-60.

Roman 1993

Roman GC, Tatemichi TK, Erkinjutti T, Cummings JL, Masdeu JC,
Garcia JH et al. Vascular dementia: diagnostic criteria for
research studies. Report of the NINDS-AIREN International
Workshop. Neurology 1993;43:250-60.

McKeith 2005

Savva 2009

McKeith IG, Dickson DW, Lowe J, Emre M, O’Brien JT, Feldman H.
Diagnosis and management of dementia with Lewy bodies third
report of the DLB Consortium. Neurology 2005;65:1863–72.

Savva GM, Wharton SB, Ince PG, Forster G, Matthews FE, Brayne
C et al. Age, neuropathology and dementia. New England
Journal of Medicine 2009;360:230-9.

McKhann 1984

Schuetz 2012

McKhann G, Drachman D, Folstein M, Katzman R, Price D,
Stadlan EM. Clinical diagnosis of Alzheimer's disease: report
of the NINCDS-ADRDA Work Group under the auspices of
Department of Health and Human Services Task Force on
Alzheimer's Disease. Neurology 1984;34(7):939–44.

Schuetz GM, Schlattmann P, Dewey M. USeo f 3x2 tables with an
intention to diagnose approach to assess clinical performance
of diagnostic tests: meta-analytical evaluation of coronary CT-
angiography studies. BMJ 2013;345:e6717.

Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the detection of dementia within community dwelling
populations (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

31

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Valcour 2000

Yamada 2008

Valcour VG, Masaki KH, Curb JD, Blanchette PL. The detection
of dementia in the primary care setting. Archives of Internal
Medicine 2000;160:2964-8.

Yamada M, Mimori Y, Kasagi F, Miyachi T, Ohshita T, Sudoh
S et al. Incidence of dementia, Alzheimers disease and
vascular dementia in a Japanese population radiation effects
Research Foundation Adult Health Study. Neuroepidemiology
2008;30:152-60.

C H A R A C T E R I S T I C S   O F   S T U D I E S

Characteristics of included studies [ordered by study ID]

Jorm 1994 

Study characteristics

Patient Sampling

Patient characteristics and setting

Community sampling (unspecified), enriched with care-home res-
idents

Community (n=945) and care-home dwelling older adults (n=100)
approached; n=684 included

Community setting

Index tests

IQCODE 16 and 26 item, English language

Target condition and reference standard(s)

Clinical dementia diagnosis using DSM IIIr, informed by the Can-
berra Interview for the Elderly

Flow and timing

Comparative

Notes

Methodological quality

Item

Of 1045 potential subjects, 769 had an informant; of this group a
clinical diagnosis was possible in 684. Timing not applicable as
cross-sectional, contemporaneous IQCODE and dementia assess-
ment

Authors' judge-
ment

Risk of bias

Applicability con-
cerns

DOMAIN 1: Patient Selection

Was a consecutive or random sample of patients enrolled?

Was a case-control design avoided?

No

Yes

Did the study avoid inappropriate exclusions?

Unclear

Could the selection of patients have introduced bias?

High risk

Are there concerns that the included patients and setting do
not match the review question?

High

DOMAIN 2: Index Test (All tests)

Were the index test results interpreted without knowledge of
the results of the reference standard?

Yes

Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the detection of dementia within community dwelling
populations (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

32

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Jorm 1994  (Continued)

If a threshold was used, was it pre-specified?

Were sufficient details given on IQCODE application for the test
to be repeated in an independent study

No

Unclear

Cochrane Database of Systematic Reviews

Could the conduct or interpretation of the index test have
introduced bias?

Unclear risk

Are there concerns that the index test, its conduct, or inter-
pretation differ from the review question?

Low concern

DOMAIN 3: Reference Standard

Is the reference standards likely to correctly classify the target
condition?

Were the reference standard results interpreted without knowl-
edge of the results of the index tests?

Were sufficient details of dementia diagnostics given for the as-
sessment to be repeated in an independent sample

Could the reference standard, its conduct, or its interpreta-
tion have introduced bias?

Are there concerns that the target condition as defined by
the reference standard does not match the question?

DOMAIN 4: Flow and Timing

Was there an appropriate interval between index test and refer-
ence standard?

Did all patients receive the same reference standard?

Were all patients included in the analysis?

Were missing IQCODE results or un-interpretable IQCODE re-
sults reported

Yes

Yes

Yes

Yes

Yes

No

Yes

Low risk

High

Could the patient flow have introduced bias?

Low risk

Jorm 1996 (psychiatry) 

Study characteristics

Patient Sampling

Subjects were ex-servicemen enrolled in a separate prospective
study

Patient characteristics and setting

Community-dwelling ex-servicemen (n=144)

Community setting

Index tests

IQCODE 16 and 26 items, English language

Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the detection of dementia within community dwelling
populations (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

33

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Jorm 1996 (psychiatry)  (Continued)

Cochrane Database of Systematic Reviews

Target condition and reference standard(s)

Clinical dementia diagnosis using ICD9

Flow and timing

Comparative

Notes

Methodological quality

Item

Of 209 potential subjects,144 had an informant and were includ-
ed. Timing not applicable as cross-sectional, contemporaneous
IQCODE and dementia assessment

These subjects were assessed by a psychiatrist

Authors' judge-
ment

Risk of bias

Applicability con-
cerns

DOMAIN 1: Patient Selection

Was a consecutive or random sample of patients enrolled?

Was a case-control design avoided?

Did the study avoid inappropriate exclusions?

Could the selection of patients have introduced bias?

Are there concerns that the included patients and setting do
not match the review question?

DOMAIN 2: Index Test (All tests)

Were the index test results interpreted without knowledge of
the results of the reference standard?

If a threshold was used, was it pre-specified?

No

Yes

No

Yes

Yes

High risk

High

Were sufficient details given on IQCODE application for the test
to be repeated in an independent study

Unclear

Could the conduct or interpretation of the index test have
introduced bias?

Low risk

Are there concerns that the index test, its conduct, or inter-
pretation differ from the review question?

Unclear

DOMAIN 3: Reference Standard

Is the reference standards likely to correctly classify the target
condition?

Were the reference standard results interpreted without knowl-
edge of the results of the index tests?

Were sufficient details of dementia diagnostics given for the as-
sessment to be repeated in an independent sample

Yes

Yes

No

Could the reference standard, its conduct, or its interpreta-
tion have introduced bias?

Low risk

Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the detection of dementia within community dwelling
populations (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

34

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane Database of Systematic Reviews

Unclear

Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Jorm 1996 (psychiatry)  (Continued)

Are there concerns that the target condition as defined by
the reference standard does not match the question?

DOMAIN 4: Flow and Timing

Was there an appropriate interval between index test and refer-
ence standard?

Unclear

Did all patients receive the same reference standard?

Were all patients included in the analysis?

Yes

No

Were missing IQCODE results or un-interpretable IQCODE re-
sults reported

Unclear

Could the patient flow have introduced bias?

High risk

Kathriarachi 2001 

Study characteristics

Patient Sampling

Stratified community sampling, using census data and door to
door assessment in a semi-urban setting

Patient characteristics and setting

Community-dwelling older adults (n=37)

Community setting

Index tests

IQCODE 26 item, Sinhalese language

Target condition and reference standard(s)

Clinical diagnosis of dementia following psychiatrist's review

Flow and timing

Comparative

Notes

Methodological quality

Item

Of 1400 potential subjects,40 were "randomly" selected for as-
sessment and 37 assessed. Timing not applicable as cross-section-
al, contemporaneous IQCODE and dementia assessment

Low numbers included and high prevalence of dementia

Authors' judge-
ment

Risk of bias

Applicability con-
cerns

DOMAIN 1: Patient Selection

Was a consecutive or random sample of patients enrolled?

Unclear

Was a case-control design avoided?

Did the study avoid inappropriate exclusions?

Yes

Yes

Could the selection of patients have introduced bias?

Unclear risk

Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the detection of dementia within community dwelling
populations (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

35

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Kathriarachi 2001  (Continued)

Are there concerns that the included patients and setting do
not match the review question?

DOMAIN 2: Index Test (All tests)

Were the index test results interpreted without knowledge of
the results of the reference standard?

Unclear

If a threshold was used, was it pre-specified?

Were sufficient details given on IQCODE application for the test
to be repeated in an independent study

No

No

Cochrane Database of Systematic Reviews

High

Could the conduct or interpretation of the index test have
introduced bias?

Unclear risk

Are there concerns that the index test, its conduct, or inter-
pretation differ from the review question?

Unclear

DOMAIN 3: Reference Standard

Is the reference standards likely to correctly classify the target
condition?

Unclear

Were the reference standard results interpreted without knowl-
edge of the results of the index tests?

Unclear

Were sufficient details of dementia diagnostics given for the as-
sessment to be repeated in an independent sample

No

Could the reference standard, its conduct, or its interpreta-
tion have introduced bias?

High risk

Are there concerns that the target condition as defined by
the reference standard does not match the question?

Unclear

DOMAIN 4: Flow and Timing

Was there an appropriate interval between index test and refer-
ence standard?

Unclear

Did all patients receive the same reference standard?

Unclear

Were all patients included in the analysis?

Were missing IQCODE results or un-interpretable IQCODE re-
sults reported

No

No

Could the patient flow have introduced bias?

High risk

Law 1995 

Study characteristics

Patient Sampling

Age stratified sample of all community residents

Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the detection of dementia within community dwelling
populations (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

36

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Law 1995  (Continued)

Cochrane Database of Systematic Reviews

Patient characteristics and setting

Randomly selected community-dwelling adults (n=237)

Community setting

Index tests

IQCODE 26 item, French language

Target condition and reference standard(s)

Clinical dementia diagnosis using DSM IIIr

Flow and timing

Comparative

Notes

Methodological quality

Item

Of 1800 potential subjects, 454 had psychiatric assessment of this
group 364 had suitable informants and 237 were included. Timing
not applicable as cross-sectional, contemporaneous IQCODE and
dementia assessment

Authors' judge-
ment

Risk of bias

Applicability con-
cerns

DOMAIN 1: Patient Selection

Was a consecutive or random sample of patients enrolled?

Unclear

Was a case-control design avoided?

Did the study avoid inappropriate exclusions?

Yes

Yes

Could the selection of patients have introduced bias?

Unclear risk

Are there concerns that the included patients and setting do
not match the review question?

Unclear

DOMAIN 2: Index Test (All tests)

Were the index test results interpreted without knowledge of
the results of the reference standard?

Unclear

If a threshold was used, was it pre-specified?

Were sufficient details given on IQCODE application for the test
to be repeated in an independent study

Yes

Yes

Could the conduct or interpretation of the index test have
introduced bias?

Unclear risk

Are there concerns that the index test, its conduct, or inter-
pretation differ from the review question?

Low concern

DOMAIN 3: Reference Standard

Is the reference standards likely to correctly classify the target
condition?

Yes

Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the detection of dementia within community dwelling
populations (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

37

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Law 1995  (Continued)

Were the reference standard results interpreted without knowl-
edge of the results of the index tests?

Unclear

Were sufficient details of dementia diagnostics given for the as-
sessment to be repeated in an independent sample

Yes

Could the reference standard, its conduct, or its interpreta-
tion have introduced bias?

Unclear risk

Are there concerns that the target condition as defined by
the reference standard does not match the question?

DOMAIN 4: Flow and Timing

Was there an appropriate interval between index test and refer-
ence standard?

Did all patients receive the same reference standard?

Were all patients included in the analysis?

Were missing IQCODE results or un-interpretable IQCODE re-
sults reported

Yes

Yes

No

Yes

Could the patient flow have introduced bias?

High risk

Low concern

Mackinnon 2003 

Study characteristics

Patient Sampling

Probability sample of older adults (age > 70 years) drawn from
electoral data

Patient characteristics and setting

Probability sampling of community cohort (n=646)

Community setting

Index tests

IQCODE 26 and 16 item, English language

Target condition and reference standard(s)

Clinical dementia diagnosis using DSM IIIr

Flow and timing

Comparative

Notes

Methodological quality

Item

DOMAIN 1: Patient Selection

Of 945 potential subjects,694 had an informant and 646 were in-
cluded. Timing not applicable as cross-sectional, contemporane-
ous IQCODE and dementia assessment

Authors' judge-
ment

Risk of bias

Applicability con-
cerns

Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the detection of dementia within community dwelling
populations (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

38

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Mackinnon 2003  (Continued)

Was a consecutive or random sample of patients enrolled?

Was a case-control design avoided?

Did the study avoid inappropriate exclusions?

Yes

Yes

Yes

Could the selection of patients have introduced bias?

Low risk

Are there concerns that the included patients and setting do
not match the review question?

Low concern

DOMAIN 2: Index Test (All tests)

Were the index test results interpreted without knowledge of
the results of the reference standard?

Unclear

If a threshold was used, was it pre-specified?

Were sufficient details given on IQCODE application for the test
to be repeated in an independent study

No

Yes

Could the conduct or interpretation of the index test have
introduced bias?

Unclear risk

Are there concerns that the index test, its conduct, or inter-
pretation differ from the review question?

Low concern

DOMAIN 3: Reference Standard

Is the reference standards likely to correctly classify the target
condition?

Yes

Were the reference standard results interpreted without knowl-
edge of the results of the index tests?

Unclear

Were sufficient details of dementia diagnostics given for the as-
sessment to be repeated in an independent sample

Yes

Could the reference standard, its conduct, or its interpreta-
tion have introduced bias?

Unclear risk

Are there concerns that the target condition as defined by
the reference standard does not match the question?

High

DOMAIN 4: Flow and Timing

Was there an appropriate interval between index test and refer-
ence standard?

Did all patients receive the same reference standard?

Were all patients included in the analysis?

Yes

Yes

No

Were missing IQCODE results or un-interpretable IQCODE re-
sults reported

Unclear

Could the patient flow have introduced bias?

Low risk

Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the detection of dementia within community dwelling
populations (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

39

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Morales 1995 

Study characteristics

Patient Sampling

Random selection of community-dwelling older adults (age > 65)
from census data with initial door to door assessment

Patient characteristics and setting

Community-dwelling adults (n=68)

Community setting

Index tests

IQCODE 26 and 17 item, Spanish language

Target condition and reference standard(s)

Clinical dementia diagnosis using DSM IIIr

Flow and timing

Comparative

Notes

Methodological quality

Item

DOMAIN 1: Patient Selection

Of 352 potential subjects, 257 agreed to assessment; 135 complet-
ed assessment and data from 68 with suitable informant informa-
tion were included. Timing not applicable as cross-sectional, con-
temporaneous IQCODE and dementia assessment

Subjects with moderate to severe dementia were not included, so
the study assesses IQCODE against "mild" dementia clinical diag-
nosis

Authors' judge-
ment

Risk of bias

Applicability con-
cerns

Was a consecutive or random sample of patients enrolled?

Was a case-control design avoided?

Did the study avoid inappropriate exclusions?

Yes

Yes

No

Could the selection of patients have introduced bias?

High risk

Are there concerns that the included patients and setting do
not match the review question?

High

DOMAIN 2: Index Test (All tests)

Were the index test results interpreted without knowledge of
the results of the reference standard?

Unclear

If a threshold was used, was it pre-specified?

Were sufficient details given on IQCODE application for the test
to be repeated in an independent study

Yes

No

Could the conduct or interpretation of the index test have
introduced bias?

Unclear risk

Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the detection of dementia within community dwelling
populations (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

40

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Morales 1995  (Continued)

Are there concerns that the index test, its conduct, or inter-
pretation differ from the review question?

DOMAIN 3: Reference Standard

Is the reference standards likely to correctly classify the target
condition?

Were the reference standard results interpreted without knowl-
edge of the results of the index tests?

Were sufficient details of dementia diagnostics given for the as-
sessment to be repeated in an independent sample

Could the reference standard, its conduct, or its interpreta-
tion have introduced bias?

Are there concerns that the target condition as defined by
the reference standard does not match the question?

DOMAIN 4: Flow and Timing

Was there an appropriate interval between index test and refer-
ence standard?

Did all patients receive the same reference standard?

Were all patients included in the analysis?

Yes

Yes

Yes

Yes

Yes

No

Cochrane Database of Systematic Reviews

Low concern

Low risk

Unclear

Were missing IQCODE results or un-interpretable IQCODE re-
sults reported

Unclear

Could the patient flow have introduced bias?

High risk

Morales 1997 (rural) 

Study characteristics

Patient Sampling

Community sampling stratified by age/sex/place of residence with
door to door assessment

Patient characteristics and setting

Community (rural) dwelling adults (n=160)

Index tests

IQCODE 26 item, Spanish language

Target condition and reference standard(s)

Clinical dementia diagnosis using DSM IIIr

Flow and timing

Comparative

Notes

Data on numbers assessed and not included are not given. Timing
not applicable as cross-sectional, contemporaneous IQCODE and
dementia assessment

This paper presents two separate cohorts; these data refer to
those living in a rural setting

Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the detection of dementia within community dwelling
populations (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

41

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Morales 1997 (rural)  (Continued)

Methodological quality

Item

DOMAIN 1: Patient Selection

Authors' judge-
ment

Risk of bias

Applicability con-
cerns

Was a consecutive or random sample of patients enrolled?

Was a case-control design avoided?

No

Yes

Did the study avoid inappropriate exclusions?

Unclear

Could the selection of patients have introduced bias?

High risk

Are there concerns that the included patients and setting do
not match the review question?

High

DOMAIN 2: Index Test (All tests)

Were the index test results interpreted without knowledge of
the results of the reference standard?

If a threshold was used, was it pre-specified?

Unclear

Unclear

Were sufficient details given on IQCODE application for the test
to be repeated in an independent study

No

Could the conduct or interpretation of the index test have
introduced bias?

High risk

Are there concerns that the index test, its conduct, or inter-
pretation differ from the review question?

Low concern

DOMAIN 3: Reference Standard

Is the reference standards likely to correctly classify the target
condition?

Were the reference standard results interpreted without knowl-
edge of the results of the index tests?

Were sufficient details of dementia diagnostics given for the as-
sessment to be repeated in an independent sample

Yes

Yes

Yes

Could the reference standard, its conduct, or its interpreta-
tion have introduced bias?

Low risk

Are there concerns that the target condition as defined by
the reference standard does not match the question?

DOMAIN 4: Flow and Timing

Was there an appropriate interval between index test and refer-
ence standard?

Unclear

Did all patients receive the same reference standard?

Yes

Low concern

Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the detection of dementia within community dwelling
populations (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

42

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Morales 1997 (rural)  (Continued)

Were all patients included in the analysis?

Were missing IQCODE results or un-interpretable IQCODE re-
sults reported

No

Yes

Cochrane Database of Systematic Reviews

Could the patient flow have introduced bias?

High risk

Morales 1997 (urban) 

Study characteristics

Patient Sampling

Community sampling stratified by age/sex/place of residence with
door to door assessment

Patient characteristics and setting

Community (urban) dwelling adults (n=97)

Community setting

Index tests

IQCODE 26 item, Spanish language

Target condition and reference standard(s)

Clinical dementia diagnosis using DSM IIIr

Flow and timing

Comparative

Notes

Methodological quality

Item

DOMAIN 1: Patient Selection

Data on numbers assessed and not included are not given. Timing
not applicable as cross-sectional, contemporaneous IQCODE and
dementia assessment

This paper presents two separate cohorts; these data refer to
those living in an urban setting

Authors' judge-
ment

Risk of bias

Applicability con-
cerns

Was a consecutive or random sample of patients enrolled?

Was a case-control design avoided?

No

Yes

Did the study avoid inappropriate exclusions?

Unclear

Could the selection of patients have introduced bias?

High risk

Are there concerns that the included patients and setting do
not match the review question?

High

DOMAIN 2: Index Test (All tests)

Were the index test results interpreted without knowledge of
the results of the reference standard?

If a threshold was used, was it pre-specified?

Unclear

Unclear

Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the detection of dementia within community dwelling
populations (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

43

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Morales 1997 (urban)  (Continued)

Were sufficient details given on IQCODE application for the test
to be repeated in an independent study

No

Could the conduct or interpretation of the index test have
introduced bias?

High risk

Are there concerns that the index test, its conduct, or inter-
pretation differ from the review question?

Low concern

Low concern

DOMAIN 3: Reference Standard

Is the reference standards likely to correctly classify the target
condition?

Were the reference standard results interpreted without knowl-
edge of the results of the index tests?

Were sufficient details of dementia diagnostics given for the as-
sessment to be repeated in an independent sample

Yes

Yes

Yes

Could the reference standard, its conduct, or its interpreta-
tion have introduced bias?

Low risk

Are there concerns that the target condition as defined by
the reference standard does not match the question?

DOMAIN 4: Flow and Timing

Was there an appropriate interval between index test and refer-
ence standard?

Unclear

Did all patients receive the same reference standard?

Were all patients included in the analysis?

Were missing IQCODE results or un-interpretable IQCODE re-
sults reported

Yes

No

Yes

Could the patient flow have introduced bias?

High risk

Senanorong 2001 

Study characteristics

Patient Sampling

"Population" study, no further detail given

Patient characteristics and setting

Community-dwelling older adults (n=160)

Community setting

Index tests

IQCODE 16 and 3 item, Thai language

Target condition and reference standard(s)

Clinical dementia diagnosis using DSM IV

Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the detection of dementia within community dwelling
populations (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

44

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Senanorong 2001  (Continued)

Flow and timing

Comparative

Notes

Methodological quality

Item

DOMAIN 1: Patient Selection

Data on numbers assessed and not included are not given. Timing
not applicable as cross-sectional, contemporaneous IQCODE and
dementia assessment

This study present two cohorts these data are from "normal educ-
tion" group. Numbers of dementia cases suggest a case-control
methodology was used but this is not specified in methodology

Authors' judge-
ment

Risk of bias

Applicability con-
cerns

Was a consecutive or random sample of patients enrolled?

Unclear

Was a case-control design avoided?

Did the study avoid inappropriate exclusions?

Unclear

Unclear

Could the selection of patients have introduced bias?

High risk

Are there concerns that the included patients and setting do
not match the review question?

High

DOMAIN 2: Index Test (All tests)

Were the index test results interpreted without knowledge of
the results of the reference standard?

Unclear

If a threshold was used, was it pre-specified?

Were sufficient details given on IQCODE application for the test
to be repeated in an independent study

Could the conduct or interpretation of the index test have
introduced bias?

Are there concerns that the index test, its conduct, or inter-
pretation differ from the review question?

DOMAIN 3: Reference Standard

Is the reference standards likely to correctly classify the target
condition?

Were the reference standard results interpreted without knowl-
edge of the results of the index tests?

Were sufficient details of dementia diagnostics given for the as-
sessment to be repeated in an independent sample

No

No

Yes

Yes

No

High risk

Unclear

Could the reference standard, its conduct, or its interpreta-
tion have introduced bias?

Low risk

Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the detection of dementia within community dwelling
populations (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

45

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane Database of Systematic Reviews

Unclear

Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Senanorong 2001  (Continued)

Are there concerns that the target condition as defined by
the reference standard does not match the question?

DOMAIN 4: Flow and Timing

Was there an appropriate interval between index test and refer-
ence standard?

Unclear

Did all patients receive the same reference standard?

Were all patients included in the analysis?

Were missing IQCODE results or un-interpretable IQCODE re-
sults reported

Unclear

Unclear

Unclear

Could the patient flow have introduced bias?

High risk

Srikanth 2006 

Study characteristics

Patient Sampling

Community-based study of all non-aphasic stroke survivors from
period 1998-1999 resident in an urban setting

Patient characteristics and setting

Community-dwelling stroke-survivors (n=79)

Community setting

Index tests

IQCODE 16 item, English language

Target condition and reference standard(s)

Clinical dementia diagnosis using DSM IV

Flow and timing

Comparative

Notes

Methodological quality

Item

Of 99 subjects, 88 were eligible for assessment and IQCODE data
were available for 79

These subjects are all stroke-survivors

Authors' judge-
ment

Risk of bias

Applicability con-
cerns

DOMAIN 1: Patient Selection

Was a consecutive or random sample of patients enrolled?

Was a case-control design avoided?

Did the study avoid inappropriate exclusions?

Yes

Yes

Yes

Could the selection of patients have introduced bias?

Low risk

Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the detection of dementia within community dwelling
populations (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

46

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Srikanth 2006  (Continued)

Are there concerns that the included patients and setting do
not match the review question?

DOMAIN 2: Index Test (All tests)

Were the index test results interpreted without knowledge of
the results of the reference standard?

If a threshold was used, was it pre-specified?

Were sufficient details given on IQCODE application for the test
to be repeated in an independent study

Unclear

Yes

Unclear

Cochrane Database of Systematic Reviews

High

Could the conduct or interpretation of the index test have
introduced bias?

Unclear risk

Are there concerns that the index test, its conduct, or inter-
pretation differ from the review question?

Unclear

DOMAIN 3: Reference Standard

Is the reference standards likely to correctly classify the target
condition?

Were the reference standard results interpreted without knowl-
edge of the results of the index tests?

Were sufficient details of dementia diagnostics given for the as-
sessment to be repeated in an independent sample

Could the reference standard, its conduct, or its interpreta-
tion have introduced bias?

Are there concerns that the target condition as defined by
the reference standard does not match the question?

DOMAIN 4: Flow and Timing

Was there an appropriate interval between index test and refer-
ence standard?

Did all patients receive the same reference standard?

Were all patients included in the analysis?

Were missing IQCODE results or un-interpretable IQCODE re-
sults reported

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Low risk

Low concern

Could the patient flow have introduced bias?

Low risk

Yamada 2011 

Study characteristics

Patient Sampling

Community study, sampling method not clear

Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the detection of dementia within community dwelling
populations (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

47

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Yamada 2011  (Continued)

Patient characteristics and setting

Cochrane Database of Systematic Reviews

Community-dwelling older adults who were participants in anoth-
er study (n=423)

Index tests

IQCODE 26 item, Japanese language

Target condition and reference standard(s)

Clinical dementia diagnosis using DSM

Flow and timing

Comparative

Notes

Methodological quality

Item

DOMAIN 1: Patient Selection

Unclear

Abstract data only

Authors' judge-
ment

Risk of bias

Applicability con-
cerns

Was a consecutive or random sample of patients enrolled?

Was a case-control design avoided?

No

Yes

Did the study avoid inappropriate exclusions?

Unclear

Could the selection of patients have introduced bias?

High risk

Are there concerns that the included patients and setting do
not match the review question?

Unclear

DOMAIN 2: Index Test (All tests)

Were the index test results interpreted without knowledge of
the results of the reference standard?

If a threshold was used, was it pre-specified?

Unclear

Unclear

Were sufficient details given on IQCODE application for the test
to be repeated in an independent study

No

Could the conduct or interpretation of the index test have
introduced bias?

Unclear risk

Are there concerns that the index test, its conduct, or inter-
pretation differ from the review question?

High

DOMAIN 3: Reference Standard

Is the reference standards likely to correctly classify the target
condition?

Yes

Were the reference standard results interpreted without knowl-
edge of the results of the index tests?

Unclear

Were sufficient details of dementia diagnostics given for the as-
sessment to be repeated in an independent sample

No

Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the detection of dementia within community dwelling
populations (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

48

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Yamada 2011  (Continued)

Cochrane Database of Systematic Reviews

Could the reference standard, its conduct, or its interpreta-
tion have introduced bias?

High risk

Low concern

Are there concerns that the target condition as defined by
the reference standard does not match the question?

DOMAIN 4: Flow and Timing

Was there an appropriate interval between index test and refer-
ence standard?

Unclear

Did all patients receive the same reference standard?

Were all patients included in the analysis?

Were missing IQCODE results or un-interpretable IQCODE re-
sults reported

Unclear

Unclear

No

Could the patient flow have introduced bias?

High risk

Characteristics of excluded studies [ordered by study ID]

Study

Abreu 2008

Butt 2008

Cherbuin 2008

de Jonge 1997

Dekkers 2009

Diefeldt 2007b

Diesfeldt 2007

Reason for exclusion

Hospital setting

Data on less than 10 participants

No new data

Data not suitable for analysis

Data not suitable for analysis

Repeat data set

No dementia diagnosis reference standard

Ehrensperger 2010

Uses unvalidated (two-year) IQCODE

Farias 2002

No dementia diagnosis reference standard

Finneli (abstract)

Data not suitable for analysis

Fuh 1995

Garcia 2002

Goncalves 2011

Hancock 2009

Harwood 1997

Case-control

Hospital setting

Hospital setting

Hospital setting

Hospital setting

Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the detection of dementia within community dwelling
populations (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

49

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study

Hayden 2003

Henon 2001

Isella 2002

Isella 2006

Jorm 1989

Jorm 1989b

Jorm 1991

Reason for exclusion

<10 IQCODE

Uses a delayed verification analysis

Uses a delayed verification analysis

Data not suitable for analysis

Data not suitable for analysis

No dementia diagnosis reference standard

Hospital setting

Jorm 1996 (Age and Ageing

No dementia diagnosis reference standard

Jorm 1997

Jorm 2000

Jorm 2003

Jorm 2004

No new data

No dementia diagnosis reference standard

No new data

No new data

Khachaturian 2000

No IQCODE index test data

Knaefelc 2003

Krogseth 2011

Larner 2010

Larner 2013

Li 2012

Louis 1999

Hospital setting

Uses a delayed verification analysis

Looks at diagnosis accuracy comparing two dementia types rather than dementia or no
dementia dichotomy

Review article

No dementia diagnosis reference standard

Uses a delayed verification analysis

Mackinnon 1998

Hospital setting

Mimori (abstract)

No new data

Morales-Gonzalez 1992

Hospital setting

Mulligan 1996

Narasimhalu 2008

Ozel-kizel 2010

Peroco 2009

Potter 2009

Hospital setting

Hospital setting

Hospital setting

Hospital setting

Data not suitable for analysis

Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the detection of dementia within community dwelling
populations (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

50

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study

Razavi 2011

Ritchie 1992

Reason for exclusion

Hospital setting

No IQCODE data

Rodriguez-Molinero 2010

No dementia diagnosis reference standard

Rovner 2012

Sanchez 2009

Schofield 2006

Sikkes 2010

Siri 2006

Starr 2000

Tang 2003

Thomas 1994

Tokuhara 2006

Data not suitable for analysis

No dementia diagnosis reference standard

Data not suitable for analysis

Hospital setting

Hospital setting

No dementia diagnosis reference standard

Hospital setting

Hospital setting

Primary care setting

Wierderholt 1999

Data not suitable for analysis

Wolfe 2009

No dementia diagnosis reference standard

Zevallos-Bustamente 2003

Hospital setting

Data not suitable for analysis

Hospital setting

Repeat data set

Repeat data set

Zhang 2003

Zhou 2002

Zhou 2003

Zhou 2004

D A T A

Presented below are all the data for all of the tests entered into the review.

Table Tests.   Data tables by test

Test

No. of studies

No. of participants

3 accuracy of IQCODE at 3.3 threshold or nearest (16 and 26 item included)

11

4 accuracy of IQCODE at 3.3 threshold (16 and 26 item IQCODE included)

5 accuracy of IQCODE at 3.4 threshold (16 and 26 item IQCODE included)

6

3

2644

1232

988

Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the detection of dementia within community dwelling
populations (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

51

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Test

No. of studies

No. of participants

6 accuracy of IQCODE at 3.5 threshold (16 and 26 item IQCODE included)

7 accuracy of IQCODE at 3.6 threshold (16 and 26 item IQCODE included)

8 16 item IQCODE 3.3 threshold

9 16 item IQCODE 3.4 threshold

10 16 item IQCODE 3.5 threshold

11 16 item IQCODE 3.6 threshold

12 26 item IQCODE 3.3 threshold

13 26 item IQCODE 3.4 threshold

14 26 item IQCODE 3.5 threshold

15 26 item IQCODE 3.6 threshold

16 all IQCODE studies at 3.3 threshold with Srikanth removed

17 all IQCODE studies at 3.4 threshold with Senanorong removed

18 all IQCODE studies at 3.5 threshold with Senanorong removed

3

3

2

3

1

1

5

1

2

2

5

2

3

1144

1215

763

988

684

646

1153

674

460

569

1153

828

1144

Test 3.   accuracy of IQCODE at 3.3 threshold or nearest (16 and 26 item included)

Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the detection of dementia within community dwelling
populations (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

52

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Test 4.   accuracy of IQCODE at 3.3 threshold (16 and 26 item IQCODE included)

Test 5.   accuracy of IQCODE at 3.4 threshold (16 and 26 item IQCODE included)

Test 6.   accuracy of IQCODE at 3.5 threshold (16 and 26 item IQCODE included)

Test 7.   accuracy of IQCODE at 3.6 threshold (16 and 26 item IQCODE included)

Test 8.   16 item IQCODE 3.3 threshold

Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the detection of dementia within community dwelling
populations (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

53

 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Test 9.   16 item IQCODE 3.4 threshold

Test 10.   16 item IQCODE 3.5 threshold

Test 11.   16 item IQCODE 3.6 threshold

Test 12.   26 item IQCODE 3.3 threshold

Test 13.   26 item IQCODE 3.4 threshold

Test 14.   26 item IQCODE 3.5 threshold

Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the detection of dementia within community dwelling
populations (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

54

 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Test 15.   26 item IQCODE 3.6 threshold

Test 16.   all IQCODE studies at 3.3 threshold with Srikanth removed

Test 17.   all IQCODE studies at 3.4 threshold with Senanorong removed

Test 18.   all IQCODE studies at 3.5 threshold with Senanorong removed

A D D I T I O N A L   T A B L E S

Table 1.   Summary of test accuracy at study level 

Study ID

Jorm 1994

Jorm (psychiatry) 1996

Kathriarachi 2001

Participants (n)

Primary thresh-
old

Sensitivity (%)

Specificity (%)

684

144

37

3.4

3.3

3.5

77

91

71

86

62

83

Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the detection of dementia within community dwelling
populations (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

55

 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Table 1.   Summary of test accuracy at study level  (Continued)

Law 1995

Mackinnon 2003

Morales 1995

Morales (rural) 1997

Morales (urban) 1997

Senanorong 2001

Srikanth 2006

Yamada 2011

Table 2.   Age of participants in included studies 

Study name

Jorm 1994

Jorm 1996 (psychiatry)

Kathriarachi 2001

Law 1995

Mackinnon 2003

Morales 1995

Morales 1997 (urban) (urban)

Morales 1997 (urban) (rural)

Senanorong 2001

Srikanth 2006

Yamada 2011

237

646

68

160

97

160

79

423

3.6

3.6

3.3

3.3

3.3

3.5

3.3

3.6

75

67

86

82

83

85

88

80

98

93

92

90

83

92

63

85

Mean age (yrs)

SD

Range (yrs)

-

72.9

-

80.7

76.5

73.1

75.2

73.5

65.7

69.0

-

-

-

-

6.5

-

5.2

6.1

8.2

5.0

14.4

-

-

66 - 83

(Recruited >65yrs only)

67 - 97

70 - 97

65 - 86

66 - 92

61 - 96

52 - 85

-

-

A P P E N D I C E S

Appendix 1. WHO International Classification of Disease - Dementia

World Health Organization International Classification of Diseases 10

F00 - F09 ORGANIC, INCLUDING SYMPTOMATIC, MENTAL DISORDERS

DEMENTIA

G1. Evidence of each of the following:

Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the detection of dementia within community dwelling
populations (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

56

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

(1) A decline in memory, which is most evident in the learning of new information, although in more severe cases, the recall of previously
learned  information  may  be  also  affected.  The  impairment  applies  to  both  verbal  and  non-verbal  material.  The  decline  should  be
objectively verified by obtaining a reliable history from an informant, supplemented, if possible, by neuropsychological tests or quantified
cognitive assessments. The severity of the decline, with mild impairment as the threshold for diagnosis, should be assessed as follows:

Mild: a degree of memory loss sufficient to interfere with everyday activities, though not so severe as to be incompatible with independent
living. The main function affected is the learning of new material. For example, the individual has difficulty in registering, storing and
recalling elements in daily living, such as where belongings have been put, social arrangements, or information recently imparted by family
members.

Moderate: A degree of memory loss which represents a serious handicap to independent living. Only highly learned or very familiar material
is retained. New information is retained only occasionally and very briefly. The individual is unable to recall basic information about where
he lives, what he has recently been doing, or the names of familiar persons.

Severe: a degree of memory loss characterized by the complete inability to retain new information. Only fragments of previously learned
information remain. The subject fails to recognize even close relatives.

(2) A decline in other cognitive abilities characterized by deterioration in judgement and thinking, such as planning and organizing, and in
the general processing of information. Evidence for this should be obtained when possible from interviewing an informant, supplemented,
if possible, by neuropsychological tests or quantified objective assessments. Deterioration from a previously higher level of performance
should be established. The severity of the decline, with mild impairment as the threshold for diagnosis, should be assessed as follows:

Mild. The decline in cognitive abilities causes impaired performance in daily living, but not to a degree making the individual dependent
on others. More complicated daily tasks or recreational activities cannot be undertaken.

Moderate.  The  decline  in  cognitive  abilities  makes  the  individual  unable  to  function  without  the  assistance  of  another  in  daily  living,
including shopping and handling money. Within the home, only simple chores are preserved. Activities are increasingly restricted and
poorly sustained.

Severe. The decline is characterized by an absence, or virtual absence, of intelligible ideation. The overall severity of the dementia is best
expressed as the level of decline in memory or other cognitive abilities, whichever is the more severe (e.g. mild decline in memory and
moderate decline in cognitive abilities indicate a dementia of moderate severity).

G2. Preserved awareness of the environment during a period of time long enough to enable the unequivocal demonstration of G1. When
there are superimposed episodes of delirium the diagnosis of dementia should be deferred.

G3. A decline in emotional control or motivation, or a change in social behaviour, manifest as at least one of the following:

(1) emotional lability;

(2) irritability;

(3) apathy;

(4) coarsening of social behaviour.

G4. For a confident clinical diagnosis, G1 should have been present for at least six months; if the period since the manifest onset is shorter,
the diagnosis can only be tentative.

Comments: The diagnosis is further supported by evidence of damage to other higher cortical functions, such as aphasia, agnosia, apraxia.

Judgment about independent living or the development of dependence (upon others) need to take account of the cultural expectation
and context.

Dementia is specified here as having a minimum duration of six months to avoid confusion with reversible states with identical behavioural
syndromes, such as traumatic subdural haemorrhage (S06.5), normal pressure hydrocephalus (G91.2) and diffuse or focal brain injury
(S06.2 and S06.3).

A fifth character may be used to indicate the presence of additional symptoms, in the categories F00-F03

(F00 Dementia in Alzheimer's disease; F01 Vascular dementia; F02 Dementia in diseases classified elsewhere; and

F03 Unspecified dementia), as follows:

.x0 without additional symptoms

Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the detection of dementia within community dwelling
populations (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

57

 
 
Cochrane Database of Systematic Reviews

Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

.x1 with other symptoms, predominantly delusional

.x2 with other symptoms, predominantly hallucinatory

.x3 with other symptoms, predominantly depressive

.x4 with other mixed symptoms

A sixth character may be used to indicate the severity of the dementia:

.xx0 mild

.xx1 moderate

.xx2 severe

As mentioned above the overall severity of the dementia depends on the level of memory or intellectual impairment, whichever is the
more severe.

F00 DEMENTIA IN ALZHEIMER'S DISEASE

A. The general criteria for dementia (G1 to G4) must be met.

B.  There  is  no  evidence  from  the  history,  physical  examination  or  special  investigations  for  any  other  possible  cause  of  dementia
(e.g.  cerebrovascular  disease,  Parkinson's  disease,  Huntington's  disease,  normal  pressure  hydrocephalus),  a  systemic  disorder  (e.g.
hypothyroidism, vit. B12 or folic acid deficiency, hypercalcaemia), or alcohol- or drug-abuse.

Comments: The diagnosis is confirmed by post mortem evidence of neurofibrillary tangles and neuritic plaques in excess of those found
in normal ageing of the brain.

The following features support the diagnosis, but are not necessary elements: Involvement of cortical functions as evidenced by aphasia,
agnosia or apraxia; decrease of motivation and drive, leading to apathy and lack of spontaneity; irritability and disinhibition of social
behaviour; evidence from special investigations that there is cerebral atrophy, particularly if this can be shown to be increasing over time.
In severe cases there may be Parkinson-like extrapyramidal changes, logoclonia, and epileptic fits.

Specification  of  features  for  possible  subtypes.  Because  of  the  possibility  that  subtypes  exist,  it  is  recommended  that  the  following
characteristics  be  ascertained  as  a  basis  for  a  further  classification:  age  at  onset;  rate  of  progression;  the  configuration  of  the  clinical
features, particularly the relative prominence (or lack) of temporal, parietal or frontal lobe signs; any neuropathological or neurochemical
abnormalities, and their pattern.

The division of AD into subtypes can at present be accomplished in two ways: first by taking only the age of onset and labelling AD as either
early or late, with an approximate cut-off point at 65 years; or secondly, by assessing how well the individual conforms to one of the two
putative syndromes, early or late onset type.  It should be noted that it is unlikely that a sharp distinction exists between early and late
onset type. Early onset type may occur in late life, just as late onset type may occasionally have an onset under the age of 65. The following
criteria may be used to differentiate F00.0 from F00.1, but it should be remembered that the status of this subdivision is still controversial.

F00.0 Dementia in Alzheimer's disease with early onset

1. The criteria for dementia in Alzheimer's disease (F00) must be met, and the age at onset being under 65 years.

2. In addition, at least one of the following requirements must be met:

(a) evidence of a relatively rapid onset and progression;

(b) in addition to memory impairment, there is aphasia (amnesic or sensory), agraphia, alexia, acalculia, or apraxia (indicating the presence
of temporal, parietal and/or frontal lobe involvement).

F00.1 Dementia in Alzheimer's disease with late onset

1. The criteria for dementia in Alzheimer's disease (F00) must be met and the age at onset must be 65 or more.

2. In addition, at least one of the following requirements must be met:

(a) evidence of a very slow, gradual onset and progression (the rate of the latter may be known only retrospectively after a course of 3
years or more);

(b) predominance of memory impairment G1.1, over intellectual impairment G1.2 (see general criteria for dementia).

Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the detection of dementia within community dwelling
populations (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

58

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

F00.2 Dementia in Alzheimer's disease, atypical or mixed type

Cochrane Database of Systematic Reviews

Use this term and code for dementias that have important atypical features or that fulfil criteria for both early and late onset type of
Alzheimer's disease. Mixed Alzheimer's and vascular dementia is also included here.

F00.9 Dementia in Alzheimer's disease, unspecified

F01 VASCULAR DEMENTIA

G1. The general criteria for dementia (G1 to G4) must be met.

G2. Unequal distribution of deficits in higher cognitive functions, with some affected and others relatively spared. Thus memory may be
quite markedly affected while thinking, reasoning and information processing may show only mild decline.

G3. There is clinical evidence of focal brain damage, manifest as at least one of the following:

(1) unilateral spastic weakness of the limbs;

(2) unilaterally increased tendon reflexes;

(3) an extensor plantar response;

(4) pseudobulbar palsy.

G4. There is evidence from the history, examination, or tests, of a significant cerebrovascular disease, which may reasonably be judged to
be etiologically related to the dementia (e.g. a history of stroke; evidence of cerebral infarction).

The following criteria may be used to differentiate subtypes of vascular dementia, but it should be remembered that the usefulness of this
subdivision may not be generally accepted.

F01.0 Vascular dementia of acute onset

A. The general criteria for vascular dementia (F01) must be met.

B. The dementia develops rapidly (i.e. usually within one month, but within no longer than three months) after a succession of strokes,
or (rarely) after a single large infarction.

F01.1 Multi-infarct dementia

A. The general criteria for vascular dementia (F01) must be met.

B. The onset of the dementia is gradual (i.e. within three to six months), following a number of minor ischaemic episodes.

Comments: It is presumed that there is an accumulation of infarcts in the cerebral parenchyma. Between the ischaemic episodes there
may be periods of actual clinical improvement.

F01.2 Subcortical vascular dementia

A. The general criteria for vascular dementia (F01) must be met.

B. A history of hypertension.

C.  Evidence  from  clinical  examination  and  special  investigations  of  vascular  disease  located  in  the  deep  white  matter  of  the  cerebral
hemispheres, with preservation of the cerebral cortex.

F01.3 Mixed cortical and subcortical vascular dementia

Mixed  cortical  and  subcortical  components  of  the  vascular  dementia  may  be  suspected  from  the  clinical  features,  the  results  of
investigations (including autopsy), or both.

F01.8 Other vascular dementia

F01.9 Vascular dementia, unspecified

F02 DEMENTIA IN OTHER DISEASES CLASSIFIED ELSEWHERE

F02.0 Dementia in Pick's disease

Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the detection of dementia within community dwelling
populations (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

59

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

A. The general criteria for dementia (G1 to G4) must be met.

B. Slow onset with steady deterioration.

C. Predominance of frontal lobe involvement evidenced by two or more of the following:

(1) emotional blunting;

(2) coarsening of social behaviour;

(3) disinhibition;

(4) apathy or restlessness;

(5) aphasia.

D. Relative preservation, in the early stages, of memory and parietal lobe functions.

F02.1 Dementia in Creutzfeldt-Jakob disease

A. The general criteria for dementia (G1 to G4) must be met.

B. Very rapid progression of the dementia, with disintegration of virtually all higher cerebral functions.

C. The emergence, usually after or simultaneously with the dementia, of one or more of the following types of neurological symptoms and
signs:

(1) pyramidal symptoms;

(2) extrapyramidal symptoms;

(3) cerebellar symptoms;

(4) aphasia;

(5) visual impairment.

Comments: An akinetic and mute state is the typical terminal stage. An amyotrophic variant may be seen, where the neurological signs
precede the onset of the dementia. A characteristic electroencephalogram (periodic spikes against a slow and low voltage background), if
present in association with the above clinical signs, will increase the probability of the diagnosis. However, the diagnosis can be confirmed
only by neuropathological examination (neuronal loss, astrocytosis, and spongiform changes). Because of the risk of infection, this should
be carried out only under special protective conditions.

F02.2 Dementia in Huntington's disease

A. The general criteria for dementia (G1 to G4) must be met.

B. Subcortical functions are affected first and dominate the picture of dementia throughout; manifest as slowness of thinking or movement
and personality alteration with apathy or depression.

C. Presence of involuntary choreiform movements, typically of the face, hands or shoulders, or in the gait. The patient may attempt to
conceal them by converting them into a voluntary action.

D. A history of Huntington's disease in one parent or a sibling; or a family history which suggests the disorder.

E. The absence of clinical features otherwise accounting for the abnormal movements.

Comments:  In  addition  to  involuntary  choreiform  movements  there  may  be  development  of  extrapyramidal  rigidity  or  spasticity  with
pyramidal signs.

F02.3 Dementia in Parkinson's disease

A. The general criteria for dementia (G1 to G4) must be met.

B. Diagnosis of Parkinson's disease.

C. Absence of cognitive impairment attributable to anti-parkinsonian medication.

Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the detection of dementia within community dwelling
populations (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

60

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

D. There is no evidence from the history, physical examination or special investigations for any other possible cause of dementia, including
other forms of brain disease, damage or dysfunction (e.g. cerebrovascular disease, HIV disease, Huntington's disease, normal pressure
hydrocephalis), a systemic disorder (e.g. hypothyroidism, vit. B12 or folic acid deficiency, hypercalcaemia), or alcohol or drug abuse.

If criteria are also fulfilled for dementia in Alzheimer's disease with late onset (F00.1), this category F00.1 should be used in combination
with Parkinson's disease G20.

F02.4 Dementia in human immunodeficiency (HIV) disease

A. The general criteria for dementia (G1 to G4) must be met.

B. Diagnosis of HIV infection.

C. There is no evidence from the history, physical examination or special investigations for any other possible cause of dementia, including
other forms of brain disease, damage or dysfunction (e.g. Alzheimer's disease, cerebrovascular disease, Parkinson's disease, Huntington's
disease, normal pressure hydrocephalis), a systemic disorder (e.g. hypothyroidism, vit. B12 or folic acid deficiency, hypercalcaemia), or
alcohol or drug abuse.

F02.8 Dementia in other specified diseases classified elsewhere

Dementia can occur as a manifestation or consequence of a variety of cerebral and somatic conditions. To specify the etiology, the ICD-10
code for the underlying condition should be added.

F03 UNSPECIFIED DEMENTIA

This category should be used when the general criteria for dementia are met, but when it is not possible to identify one of the specific
types (F00.0-F02.9).

Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision

Dementia Codes

Dementia of the Alzheimer’s Type, with early onset

294.10 Without behavioural disturbance

294.11 With behavioural disturbance

Dementia of the Alzheimer’s Type, with late onset

294.10 Without behavioural disturbance

294.11 With behavioural disturbance

Vascular dementia

290.40 Uncomplicated

290.41 With delirium

290.42 With delusions

290.43 With depressed mood

Dementia due to HIV disease

294.10 Without behavioural disturbance

294.11 With behavioural disturbance

Dementia due to head trauma

294.10 Without behavioural disturbance

294.11 With behavioural disturbance

Dementia due to Parkinson's disease

294.10 Without behavioural disturbance

Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the detection of dementia within community dwelling
populations (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

61

 
 
Cochrane Database of Systematic Reviews

Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

294.11 With behavioural disturbance

Dementia due to Huntington's disease

294.10 Without behavioural disturbance

294.11 With behavioural disturbance

Dementia due to Pick’s disease

294.10 Without behavioural disturbance

294.11 With behavioural disturbance

Dementia due to Creutzfeldt-Jakob Disease

294.10 Without behavioural disturbance

294.11 With behavioural disturbance

Dementia due to... [indicate other general medical condition]

294.10 Without behavioural disturbance

294.11 With behavioural disturbance

294.8 Dementia NOS

Appendix 2. Twenty-six item IQCODE

Instructions: Now we want you to remember what your friend or relative was like 10 years ago and to compare it with what he/she is like
now. 10 years ago was 19__. On the next page are situations where this person has to use his/her memory or intelligence and we want you
to indicate whether this has improved, stayed the same or got worse than in that situation over the past 10 years. Note the importance of
comparing his/her present performance with 10 years ago. So if 10 years ago this person always forgot where he/she had left things and
he/she still does this, then this would be considered ‘Not much change’. Please indicate the changes you have observed by circling the
appropriate answer.

1. Recognizing the faces of family and
friends

1

Much im-
proved

2. Remembering the names of family and
friends

Much im-
proved

3. Remembering things about family and
friends e.g. occupations, birthdays, address-
es

Much im-
proved

4. Remembering things that have happened
recently

Much im-
proved

5. Recalling conversations a few days later

Much im-
proved

2

A bit

improved

A bit

improved

A bit

improved

A bit

improved

A bit

improved

3

Not much
change

Not much
change

Not much
change

Not much
change

Not much
change

4

A bit

worse

A bit

worse

A bit

worse

A bit

worse

A bit

worse

5

Much worse

Much worse

Much worse

Much worse

Much worse

Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the detection of dementia within community dwelling
populations (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

62

 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

  (Continued)

6. Forgetting what he/she wanted to say in
the middle of a conversation

Much im-
proved

7. Remembering his/her address and tele-
phone number

Much im-
proved

8. Remembering what day and month it is

Much im-
proved

9. Remembering where things are usually
kept

Much im-
proved

10. Remembering where to find things which
have been put in a different place from usual

Much im-
proved

11. Adjusting to any change in his/her day-
to-day routine

Much im-
proved

12. Knowing how to work familiar machines
around the house

Much im-
proved

13. Learning to use a new gadget or machine
around the house

Much im-
proved

14. Learning new things in general

Much im-
proved

15. Remembering things that happened to
him/her when he/she was young

Much im-
proved

16. Remembering things he/she learned
when he/she was young

Much im-
proved

17.  Understanding the meaning of unusual
words

Much im-
proved

18.  Understanding magazine or newspaper
articles

Much im-
proved

Cochrane Database of Systematic Reviews

A bit

improved

A bit

improved

A bit

improved

A bit

improved

A bit

improved

A bit

improved

A bit

improved

A bit

improved

A bit

improved

A bit

improved

A bit

improved

A bit

improved

A bit

Not much
change

Not much
change

Not much
change

Not much
change

Not much
change

Not much
change

Not much
change

Not much
change

Not much
change

Not much
change

Not much
change

Not much
change

Not much
change

A bit

worse

A bit

worse

A bit

worse

A bit

worse

A bit

worse

A bit

worse

A bit

worse

A bit

worse

A bit

worse

A bit

worse

A bit

worse

A bit

worse

A bit

Much worse

Much worse

Much worse

Much worse

Much worse

Much worse

Much worse

Much worse

Much worse

Much worse

Much worse

Much worse

Much worse

Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the detection of dementia within community dwelling
populations (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

63

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

  (Continued)

19.  Following a story in a book or on TV

Much im-
proved

20. Composing a letter to friends or for busi-
ness purposes

Much im-
proved

21. Knowing about important historical
events of the past

Much im-
proved

22. Making decisions on everyday matters

23. Handling money for shopping

Much im-
proved

Much im-
proved

24. Handling financial matters, e.g. the pen-
sion, dealing with the bank

Much im-
proved

25. Handling other everyday arithmetic
problems, e.g. knowing how much food to
buy, knowing how long between visits from
family or friends

Much im-
proved

improved

A bit

improved

A bit

improved

A bit

improved

A bit

improved

A bit

improved

A bit

improved

A bit

improved

Not much
change

Not much
change

Not much
change

Not much
change

Not much
change

Not much
change

Not much
change

26. Using his/her intelligence to under-
stand what's going on and to reason things
through

Much im-
proved

A bit

improved

Not much
change

Cochrane Database of Systematic Reviews

worse

A bit

worse

A bit

worse

A bit

worse

A bit

worse

A bit

worse

A bit

worse

A bit

worse

A bit

worse

Much worse

Much worse

Much worse

Much worse

Much worse

Much worse

Much worse

Much worse

Appendix 3. Sixteen-item IQCODE

Instructions: Now we want you to remember what your friend or relative was like 10 years ago and to compare it with what he/she is like
now. 10 years ago was 19__. On the next page are situations where this person has to use his/her memory or intelligence and we want you
to indicate whether this has improved, stayed the same or got worse than in that situation over the past 10 years. Note the importance of
comparing his/her present performance with 10 years ago. So if 10 years ago this person always forgot where he/she had left things and
he/she still does this, then this would be considered ‘Not much change’. Please indicate the changes you have observed by circling the
appropriate answer.

1

Remembering things about family and
friends, e.g. occupations, birthdays, ad-
dresses

Much im-
proved

A bit im-
proved

Not much
change

A bit worse

Much
worse

1

2

3

4

5

Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the detection of dementia within community dwelling
populations (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

64

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

  (Continued)

Cochrane Database of Systematic Reviews

Remembering things that have happened
recently

Much im-
proved

A bit im-
proved

Not much
change

A bit worse

Much
worse

Recalling conversations a few days later

Much im-
proved

A bit im-
proved

Not much
change

A bit worse

Much

Remembering her/his address and tele-
phone number

Much im-
proved

A bit im-
proved

Not much
change

A bit worse

Remembering what day and month it is

Much im-
proved

A bit im-
proved

Not much
change

A bit worse

Remembering where things are usually
kept

Much im-
proved

A bit im-
proved

Not much
change

A bit worse

Remembering where to find things which
have been put in a different place from
usual

Much im-
proved

A bit im-
proved

Not much
change

A bit worse

Knowing how to work familiar machines
around the house

Much im-
proved

A bit im-
proved

Not much
change

A bit worse

Learning to use a new gadget or machine
around the house

Much im-
proved

A bit im-
proved

Not much
change

A bit worse

Learning new things in general

Much im-
proved

A bit im-
proved

Not much
change

A bit worse

Following a story in a book or on TV

Much im-
proved

A bit im-
proved

Not much
change

A bit worse

Making decisions on everyday matters

Much im-
proved

A bit im-
proved

Not much
change

A bit worse

Handling money for shopping

Much im-
proved

A bit im-
proved

Not much
change

A bit worse

Handling financial matters, e.g. the pen-
sion, dealing with the bank

Much im-
proved

A bit im-
proved

Not much
change

A bit worse

Much im-
proved

A bit im-
proved

Not much
change

A bit worse

Handling other everyday arithmetic prob-
lems, e.g. knowing how much food to buy,
knowing how long between visits from
family or friends

Using his/her intelligence to understand
what’s going on and to reason things
through

Much im-
proved

A bit im-
proved

Not much
change

A bit worse

Much
worse

worse

Much
worse

Much
worse

Much
worse

Much
worse

Much
worse

Much
worse

Much
worse

Much
worse

Much
worse

Much
worse

Much
worse

Much
worse

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

Appendix 4. Sources searched and search strategies

Source

Search strategy

Hits retrieved

Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the detection of dementia within community dwelling
populations (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

65

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

  (Continued)

1. MEDLINE In-Orocess
and other non-indexed
citations and MEDLINE
1950-present (OvidSP)

1. IQCODE.ti,ab.

Apr 2011: 291

2. "informant questionnaire on cognitive decline in the elderly".ti,ab.

Jul 2012: 39

3. "IQ code".ti,ab.

Jan 2013: 19

4. ("informant* questionnair*" adj3 (dement* or screening)).ti,ab.

5. ("screening test*" adj2 (dement* or alzheimer*)).ti,ab.

6. or/1-5

2. EMBASE

1. IQCODE.ti,ab.

Apr 2011: 356

1980-2013 January 10
(OvidSP)

2. "informant questionnaire on cognitive decline in the elderly".ti,ab.

Jul 2012: 49

3. "IQ code".ti,ab.

Jan 2013: 44

4. ("informant* questionnair*" adj3 (dement* or screening)).ti,ab.

5. ("screening test*" adj2 (dement* or alzheimer*)).ti,ab.

6. or/1-5

3. PsycINFO

1. IQCODE.ti,ab.

Apr 2011: 215

1806-January week 2
2013 (OvidSP)

2. "informant questionnaire on cognitive decline in the elderly".ti,ab.

Jul 2012: 28

3. "IQ code".ti,ab.

Jan 2013: 17

4. ("informant* questionnair*" adj3 (dement* or screening)).ti,ab.

5. ("screening test*" adj2 (dement* or alzheimer*)).ti,ab.

6. or/1-5

4. BIOSIS Previews 1926
to present (ISI Web of
Knowledge)

 Topic=(IQCODE OR "informant questionnaire on cognitive decline in the el-
derly" OR "IQ code") AND Topic=(dement* OR alzheimer* OR FTLD OR FTD OR
"primary progressive aphasia" OR "progressive non-fluent aphasia" OR "fron-
totemporal lobar degeneration" OR "frontolobar degeneration" OR "frontal lo-
bar degeneration" OR "pick* disease" OR "lewy bod*")

Apr 2011: 84

Jul 2012: 12

Jan 2013: 2

Timespan=All Years. Databases=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-
SSH, BKCI-S, BKCI-SSH.

Lemmatization=On  

5. Web of Science and
conference proceedings
(1945-present)

Topic=(IQCODE OR "informant questionnaire on cognitive decline in the el-
derly" OR "IQ code") AND Topic=(dement* OR alzheimer* OR FTLD OR FTD OR
"primary progressive aphasia" OR "progressive non-fluent aphasia" OR "fron-
totemporal lobar degeneration" OR "frontolobar degeneration" OR "frontal lo-
bar degeneration" OR "pick* disease" OR "lewy bod*")

Apr 2011: 184

Jul 2012: 24

Jan 2013: 13

Timespan=All Years. Databases=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-
SSH, BKCI-S, BKCI-SSH.

Lemmatization=On  

6. LILACS (BIREME)

“short-IQCODE” OR IQCODE OR “IQ code” OR “Informant Questionnaire” OR
“Informant Questionnaires”

Apr 2011: 10

Jul 2012: 0

Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the detection of dementia within community dwelling
populations (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

66

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

  (Continued)

7. CINAHL (EBSCOhost)

S1 TX IQCODE 

S2 TX "informant questionnaire"

S3 TX "IQ code"

S4 TX screening instrument 

S5 S1 or S2 or S3 or S4 

S6 (MM "Dementia+") 

S7 TX dement*

S8 TX alzheimer* 

S9 S6 or S7 or S8 

S10 S5 and S9

Cochrane Database of Systematic Reviews

Jan 2013: 0

Apr 2011: 231

Jul 2012: 53

Jan 2013: 12

8. Additional other review sources: MEDION database (searched 31 Jan for all dates); Database of Ab-
stracts of Reviews of Effects (searched Issue 1 of the Cochrane Library 2013); Health Technology Assess-
ments Database (searched Issue 1 of the Cochrane Library 2013); ARIF: Aggressive Research Intelligence
Facility www.arif.bham.ac.uk (searched 31 Jan for all dates). Terms used: IQCODE, "IQ code", "Informant
Questionnaire", "Informant Questionnaires".

Jan 2013: 3

9 ALOIS (see Appendix 5 for the Medline strategy used to populate ALOIS)

TOTAL before de-duplication of search results

TOTAL after de-duplication and first-assess by the Trials Search Co-ordinator

Jan 2013: 22

Apr 2011: 1361

Jul 2012: 215

Jan 2013: 107 (+3 from
additional review
sources)

TOTAL: 1708

69

Appendix 5. Search strategy (MEDLINE OvidSP) run for specialised register (ALOIS)

Search strategy (MEDLINE OvidSP) run for specialised register (ALOIS)

Search narrative: The searches detailed above are very simple, single concept strategies based on the index test (IQCODE). This is a sensitive
approach to take. More complex and developed searches are run each month for the dementia group.

Every month the following strategy is run in Medline (via Ovid SP), with similar strategies run in Embase (via Ovid SP) and PsycINFO (via
Ovid SP). The results are screened based on a reading of title and abstract. The full texts (where there is one) are then obtained and a few
key details about each study are extracted including Index test/s and details of population and setting. For this review it was expected that
most studies would be identified through a search of multiple sources based on one concept (the index test in question). However, we
felt it was worth also searching ALOIS for any studies which had evaluated the accuracy of IQCODE but had not referred to it in the title
or abstract of the reference.

MEDLINE In-Process and oth-
er non-indexed citations

1. "word recall".ti,ab.

2. "7-minute screen".ti,ab.

Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the detection of dementia within community dwelling
populations (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

67

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

and MEDLINE 1950-present
(OvidSP)

3. "6 item cognitive impairment test".ti,ab.

4. "6 CIT".ti,ab.

5. "AB cognitive screen".ti,ab.

6. "abbreviated mental test".ti,ab.

7. "ADAS-cog".ti,ab.

8. AD8.ti,ab.

9. "inform* interview".ti,ab.

10. "animal fluency test".ti,ab.

11. "brief alzheimer* screen".ti,ab.

12. "brief cognitive scale".ti,ab.

13. "clinical dementia rating scale".ti,ab.

14. "clinical dementia test".ti,ab.

15. "community screening interview for dementia".ti,ab.

16. "cognitive abilities screening instrument".ti,ab.

17. "cognitive assessment screening test".ti,ab.

18. "cognitive capacity screening examination".ti,ab.

19. "clock drawing test".ti,ab.

20. "deterioration cognitive observee".ti,ab.

21. "Dem Tect".ti,ab.

22. "fuld object memory evaluation".ti,ab.

23. "IQCODE".ti,ab.

24. "mattis dementia rating scale".ti,ab.

25. "memory impairment screen".ti,ab.

26. "minnesota cognitive acuity screen".ti,ab.

27. "mini-cog".ti,ab.

28. "mini-mental state exam*".ti,ab.

29. "mmse".ti,ab.

30. "modified mini-mental state exam".ti,ab.

31. "3MS".ti,ab.

32. "neurobehavioural cognitive status exam*".ti,ab.

33. "cognistat".ti,ab.

34. "quick cognitive screening test".ti,ab.

35. "QCST".ti,ab.

36. "rapid dementia screening test".ti,ab.

Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the detection of dementia within community dwelling
populations (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

68

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

  (Continued)

37. "RDST".ti,ab.

Cochrane Database of Systematic Reviews

38. "repeatable battery for the assessment of neuropsychological status".ti,ab.

39. "RBANS".ti,ab.

40. "rowland universal dementia assessment scale".ti,ab.

41. "rudas".ti,ab.

42. "self-administered gerocognitive exam*".ti,ab.

43. ("self-administered" and "SAGE").ti,ab.

44. "self-administered computerized screening test for dementia".ti,ab.

45. "short and sweet screening instrument".ti,ab.

46. "sassi".ti,ab.

47. "short cognitive performance test".ti,ab.

48. "syndrome kurztest".ti,ab.

49. "six item screener".ti,ab.

50. "short memory questionnaire".ti,ab.

51. ("short memory questionnaire" and "SMQ").ti,ab.

52. "short orientation memory concentration test".ti,ab.

53. "s-omc".ti,ab.

54. "short blessed test".ti,ab.

55. "short portable mental status questionnaire".ti,ab.

56. "spmsq".ti,ab.

57. "short test of mental status".ti,ab.

58. "telephone interview of cognitive status modified".ti,ab.

59. "tics-m".ti,ab.

60. "trail making test".ti,ab.

61. "verbal fluency categories".ti,ab.

62. "WORLD test".ti,ab.

63. "general practitioner assessment of cognition".ti,ab.

64. "GPCOG".ti,ab.

65. "Hopkins verbal learning test".ti,ab.

66. "HVLT".ti,ab.

67. "time and change test".ti,ab.

68. "modified world test".ti,ab.

69. "symptoms of dementia screener".ti,ab.

70. "dementia questionnaire".ti,ab.

Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the detection of dementia within community dwelling
populations (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

69

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

  (Continued)

71. "7MS".ti,ab.

Cochrane Database of Systematic Reviews

72. ("concord informant dementia scale" or CIDS).ti,ab.

73. (SAPH or "dementia screening and perceived harm*").ti,ab.

74. or/1-73

75. exp Dementia/

76. Delirium, Dementia, Amnestic, Cognitive Disorders/

77. dement*.ti,ab.

78. alzheimer*.ti,ab.

79. AD.ti,ab.

80. ("lewy bod*" or DLB or LBD).ti,ab.

81. "cognit* impair*".ti,ab.

82. (cognit* adj4 (disorder* or declin* or fail* or function*)).ti,ab.

83. (memory adj3 (complain* or declin* or function*)).ti,ab.

84. or/75-83

85. exp "sensitivity and specificity"/

86. "reproducibility of results"/

87. (predict* adj3 (dement* or AD or alzheimer*)).ti,ab.

88. (identif* adj3 (dement* or AD or alzheimer*)).ti,ab.

89. (discriminat* adj3 (dement* or AD or alzheimer*)).ti,ab.

90. (distinguish* adj3 (dement* or AD or alzheimer*)).ti,ab.

91. (differenti* adj3 (dement* or AD or alzheimer*)).ti,ab.

92. diagnos*.ti.

93. di.fs.

94. sensitivit*.ab.

95. specificit*.ab.

96. (ROC or "receiver operat*").ab.

97. Area under curve/

98. ("Area under curve" or AUC).ab.

99. (detect* adj3 (dement* or AD or alzheimer*)).ti,ab.

100. sROC.ab.

101. accura*.ti,ab.

102. (likelihood adj3 (ratio* or function*)).ab.

103. (conver* adj3 (dement* or AD or alzheimer*)).ti,ab.

104. ((true or false) adj3 (positive* or negative*)).ab.

Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the detection of dementia within community dwelling
populations (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

70

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

  (Continued)

105. ((positive* or negative* or false or true) adj3 rate*).ti,ab.

106. or/85-105

107. exp dementia/di

108. Cognition Disorders/di [Diagnosis]

109. Memory Disorders/di

110. or/107-109

111. *Neuropsychological Tests/

112. *Questionnaires/

113. Geriatric Assessment/mt

114. *Geriatric Assessment/

115. Neuropsychological Tests/mt, st

116. "neuropsychological test*".ti,ab.

117. (neuropsychological adj (assess* or evaluat* or test*)).ti,ab.

118. (neuropsychological adj (assess* or evaluat* or test* or exam* or battery)).ti,ab.

119. Self report/

120. self-assessment/ or diagnostic self evaluation/

121. Mass Screening/

122. early diagnosis/

123. or/111-122

124. 74 or 123

125. 110 and 124

126. 74 or 123

127. 84 and 106 and 126

128. 74 and 106

129. 125 or 127 or 128

130. (animals not (humans and animals)).sh.

131. 129 not 130

The concepts for this are:

A Specific neuropsychological tests

B General terms (both free text and MeSH) for tests/testing/screening

C Outcome: dementia diagnosis (unfocused MeSH with diagnostic sub-headings)

D Condition of interest: Dementia (general dementia terms both free text and MeSH – exploded and
unfocused)

E Methodological filter: not used to limit all search

The concept combinations are:

Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the detection of dementia within community dwelling
populations (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

71

 
 
Cochrane Database of Systematic Reviews

Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

  (Continued)

1. (A OR B) AND C

2. (A OR B) AND D AND E

3. A AND E

Appendix 6. Assessment of reporting quality - STARD checklist

Section and Topic

TITLE/ABSTRACT

KEYWORDS

INTRODUCTION

METHODS

Participants

Test methods

1

2

3

4

5

6

7

8

9

10

11

Statistical methods

12

Identify the article as a study of diagnostic accuracy (recommend MeSH head-
ing 'sensitivity and specificity').

State the research questions or study aims, such as estimating diagnostic ac-
curacy or comparing accuracy between tests or across participant groups.

The study population: The inclusion and exclusion criteria, setting and loca-
tions where data were collected.

Participant recruitment: Was recruitment based on presenting symptoms, re-
sults from previous tests, or the fact that the participants had received the in-
dex tests or the reference standard?

Participant sampling: Was the study population a consecutive series of partic-
ipants defined by the selection criteria in item 3 and 4? If not, specify how par-
ticipants were further selected.

Data collection: Was data collection planned before the index test and ref-
erence standard were performed (prospective study) or after (retrospective
study)?

The reference standard and its rationale.

Technical specifications of material and methods involved including how and
when measurements were taken, and/or cite references for index tests and ref-
erence standard.

Definition of and rationale for the units, cut-offs and/or categories of the re-
sults of the index tests and the reference standard.

The number, training and expertise of the persons executing and reading the
index tests and the reference standard.

Whether or not the readers of the index tests and reference standard were
blind (masked) to the results of the other test and describe any other clinical
information available to the readers.

Methods for calculating or comparing measures of diagnostic accuracy, and
the statistical methods used to quantify uncertainty (e.g. 95% confidence in-
tervals).

Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the detection of dementia within community dwelling
populations (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

72

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

  (Continued)

RESULTS

Participants

Test results

Estimates

DISCUSSION

13

14

15

16

17

18

19

20

21

22

23

24

25

Methods for calculating test reproducibility, if done.

When study was performed, including beginning and end dates of recruitment.

Clinical and demographic characteristics of the study population (at least in-
formation on age, gender, spectrum of presenting symptoms).

The number of participants satisfying the criteria for inclusion who did or did
not undergo the index tests and/or the reference standard; describe why par-
ticipants failed to undergo either test (a flow diagram is strongly recommend-
ed).

Time-interval between the index tests and the reference standard, and any
treatment administered in between.

Distribution of severity of disease (define criteria) in those with the target con-
dition; other diagnoses in participants without the target condition.

A cross tabulation of the results of the index tests (including indeterminate
and missing results) by the results of the reference standard; for continuous
results, the distribution of the test results by the results of the reference stan-
dard.

Any adverse events from performing the index tests or the reference standard.

Estimates of diagnostic accuracy and measures of statistical uncertainty (e.g.
95% confidence intervals).

How indeterminate results, missing data and outliers of the index tests were
handled.

Estimates of variability of diagnostic accuracy between subgroups of partici-
pants, readers or centres, if done.

Estimates of test reproducibility, if done.    

Discuss the clinical applicability of the study findings.

Appendix 7. Assessment of methodological quality table QUADAS-2 tool

DOMAIN

PATIENT SELECTION  

INDEX TEST 

REFERENCE STANDARD

FLOW AND TIMING 

Description

Describe methods of
patient selection: De-
scribe included patients
(prior testing, presenta-
tion, intended use of in-
dex test and setting): 

Describe the index test
and how it was con-
ducted and interpret-
ed: 

Describe the reference
standard and how it was
conducted and interpret-
ed: 

Describe any patients who did
not receive the index test(s)
and/or reference standard or
who were excluded from the
2x2 table (refer to flow dia-
gram): Describe the time inter-
val and any interventions be-
tween index test(s) and refer-
ence standard:

Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the detection of dementia within community dwelling
populations (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

73

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

  (Continued)

Signalling ques-
tions

(yes/no/unclear)

Was a consecutive or
random sample of pa-
tients enrolled?

Was a case-control de-
sign avoided?

Did the study avoid in-
appropriate exclusions?

Were the index test re-
sults interpreted with-
out knowledge of the
results of the refer-
ence standard?

If a threshold was
used, was it pre-speci-
fied?

Cochrane Database of Systematic Reviews

Is the reference standard
likely to correctly classify
the target condition?

Was there an appropriate in-
terval between index test(s)
and reference standard?

Were the reference stan-
dard results interpreted
without knowledge of
the results of the index
test?

Did all patients receive a refer-
ence standard?

Did all patients receive the
same reference standard?

Were all patients included in
the analysis?

Could the patient flow have in-
troduced bias? 

Risk of bias:
High/low/ un-
clear

Could the selection of
patients have intro-
duced bias?

Could the conduct or
interpretation of the
index test have intro-
duced bias?      

Could the reference stan-
dard, its conduct, or its
interpretation have intro-
duced bias?

Concerns regard-
ing applicabili-
ty: High/low/ un-
clear

Are there concerns that
the included patients
do not match the re-
view question?

Are there concerns
that the index test, its
conduct, or interpreta-
tion differ from the re-
view question?

Are there concerns that
the target condition as
defined by the reference
standard does not match
the review question?

Appendix 8. Anchoring statements for quality assessment of IQCODE diagnostic studies

We provide some core anchoring statements for quality assessment of diagnostic test accuracy reviews of IQCODE in dementia. These
statements are designed for use with the QUADAS-2 tool and were derived during a two-day, multidisciplinary focus group.

During the focus group and the piloting/validation of this guidance, it was clear that certain issues were key to assessing quality, while
other issues were important to record but less important for assessing overall quality. To assist, we describe a 'weighting' system.  Where
an item is weighted 'high risk' then that section of the QUADAS-2 results table is likely to be scored as high risk of bias.  For example, in
dementia diagnostic test accuracy studies, ensuring that clinicians performing dementia assessment are blinded to results of index test
is fundamental. If this blinding was not present then the item on reference standard should be scored 'high risk of bias', regardless of the
other contributory elements.

In assessing individual items, the score of unclear should only be given if there is genuine uncertainty.  In these situations review authors
will contact the relevant study teams for additional information.

Anchoring statements to assist with assessment for risk of bias

Patient selection

Was a case-control or similar design avoided?

Designs  similar  to  case  control  that  may  introduce  bias  are  those  designs  where  the  study  team  deliberately  increase  or  decrease  the
proportion  of  patients  with  the  target  condition.  For  example,  a  population  study  may  be  enriched  with  extra  dementia  patients  from
a  secondary  care  setting.  Such  studies  will  be  automatically  labelled  high  risk  of  balance  and  will  be  assessed  as  a  potential  source  of
heterogeneity.

Weighting: High risk of bias

We did not include papers with case-control or "enriched" populations.

Was the sampling method appropriate?

Where sampling is used, the designs least likely to cause bias are consecutive sampling or random sampling. Sampling that is based on
volunteers or selecting participants from a clinic or research resource is prone to bias.

Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the detection of dementia within community dwelling
populations (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

74

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Weighting: High risk of bias

Are exclusion criteria described and appropriate?

Cochrane Database of Systematic Reviews

The study will be automatically graded as unclear if exclusions are not detailed (pending contact with study authors). Where exclusions are
detailed, the study will be graded as “low risk” if exclusions are felt to be appropriate by the review authors.  Certain exclusions common
to many studies of dementia are: medical instability; terminal disease; alcohol/substance misuse; concomitant psychiatric diagnosis; other
neurodegenerative condition. For a community sample we would expect relatively few exclusions.

Post hoc exclusions will be labelled “high risk” of bias.

Weighting: Low risk

Index Test

Was IQCODE assessment performed without knowledge of clinical dementia diagnosis?

Terms such as “blinded” or “independently and without knowledge of” are sufficient and full details of the blinding procedure are not required.
This item may be scored as “low risk” if explicitly described or if there is a clear temporal pattern to order of testing that precludes the need
for formal blinding  i.e. all IQCODE assessments performed before dementia assessment.

Weighting: High risk

Were IQCODE thresholds pre-specified?

For scales there is often a reference point (in units or categories) above which participants are classified as “test positive”; this may be referred
to as threshold; clinical cut-off or dichotomisation point.  A study is classified high risk of bias if the authors define the optimal cut-off post-
hoc based on their own study data. Certain papers may use an alternative methodology for analysis that does not use thresholds and these
papers should be classified as not applicable.

Weighting: Low risk

Were sufficient data on IQCODE application given for the test to be repeated in an independent study?

Particular points of interest for IQCODE include method of administration (for example, self-completed questionnaire versus direct questioning
interview); nature of informant; language of assessment.  If a novel form of IQCODE is used, details of the scale should be included or a reference
given to an appropriate descriptive text.  Where IQCODE is used in a novel manner, for example, a translated questionnaire, there should be
evidence of validation.

Weighting: Low risk

Reference Standard

Is the assessment used for clinical diagnosis of dementia acceptable?

Commonly used international criteria to assist with clinical diagnosis of dementia include those detailed in DSM-IV and ICD-10. Criteria specific
to dementia subtypes include but are not limited to NINCDS-ADRDA criteria for Alzheimer’s dementia; McKeith criteria for Lewy Body dementia;
Lund criteria for frontotemporal dementias; and the NINDS-AIREN criteria for vascular dementia. Where the criteria used for assessment is
not familiar to the review authors and the Cochrane Dementia and Cognitive Improvement group this item should be classified as “high risk
of bias”.

Weighting: High risk

Was clinical assessment for dementia performed without knowledge of IQCODE?

Terms such as “blinded” or “independent” are sufficient and full details of the blinding procedure are not required. This may be scored as “low
risk” if explicitly described or if there is a clear temporal pattern to order of testing i.e. all dementia assessments performed before IQCODE
testing.

Informant rating scales and direct cognitive tests present certain problems.  It is accepted that informant interview and cognitive testing is
a usual component of clinical assessment for dementia, however, specific use of the scale under review in the clinical dementia assessment
should be scored as high risk of bias. We have pre-specified that dementia diagnosis that explicitly uses IQCODEwill be classified as high risk
of bias.

Weighting: High risk

Were sufficient data on dementia assessment method given for the assessment to be repeated in an independent study?

Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the detection of dementia within community dwelling
populations (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

75

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

The  criteria  used  for  clinical  assessment  are  discussed  in  another  item.  Particular  points  of  interest  for  dementia  assessment  include
the  background  of  the  assessor,  training/expertise  of  the  assessor;  additional  information  available  to  inform  diagnosis  (neuroimaging;
neuropsychological testing).

Weighting: Low risk

Patient flow

Was there an appropriate interval between IQCODE and clinical dementia assessment.

For  a  cross-sectional  study  design,  there  is  potential  for  the  patient  to  change  between  assessments.  The  ideal  would  be  same  day
assessment. We have set an arbitrary  maximum interval of one month between tests, although this may be revised depending on the test and
the stability of the condition of interest.

Weighting: High

Did all patients get the same assessment for dementia regardless of IQCODE result?

There may be scenarios where only those patients who score “test positive” on IQCODE have a more detailed assessment.  Where dementia
assessment (or other reference standard) differs between patients this should be classified as high risk of bias.

Weighting: High risk

Were all patients who received IQCODE assessment included in the final analysis?

If dropouts these should be accounted for; a maximum proportion of drop outs to remain low risk of bias has been specified as 20%.

Weighting: Low risk

Were missing IQCODE results or un-interpretable IQCODE results reported?

Where missing results are reported if there is substantial attrition (we have set an arbitrary value of  50% missing data) this should be scored
as high risk of bias.

Weighting: Low risk

Applicability

Were included patients representative of the general population of interest?

The included patients should match the intended population as described in the review question.  If not already specified in the review inclusion
criteria, setting will be particularly important – the review authors should consider population in terms of symptoms; pre-testing; potential
disease prevalence.  Studies that use very selected patients or subgroups will be classified as poor applicability.

Was IQCODE performed consistently and in a manner similar to its use in clinical practice?

IQCODE studies will be judged against the original description of its use.

Was clinical diagnosis of dementia (or other reference standard) made in a manner similar to current clinical practice?

For many reviews, inclusion criteria and assessment for risk of bias will already have assessed the dementia diagnosis.  For certain reviews
an applicability statement relating to reference standard may not be applicable. There is the possibility that a form of dementia assessment,
although valid, may diagnose a far larger proportion of patients with disease than usual clinical practice. In this instance the item should be
rated poor applicability.

Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the detection of dementia within community dwelling
populations (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

76

 
 
Appendix 9. STARD (reporting quality) results

Methods

Results

Author

Ti-
tle

In-
tro

Participants

Test methods

Statistics

Participants

Estimates

Dis-
cus-
sion

Item
1

Item
2

Item
3

Item
4

Item
5

Item
6

Item
7

Item
8

Item
9

Item
10

Item
11

Item
12

Item
13

Item
14

Item
15

Item
16

Fuh 1995

no

yes

yes

yes

yes

un-
clear

yes

yes

yes

yes

yes

yes

no

no

yes

Jorm 1996

no

no

yes

yes

yes

yes

yes

yes

no

yes

yes

no

no

par-
tial-
ly

Item
21

par-
tially

Item
22

Item
23

Item
24

Item
25

no

no

no

yes

yes

no

no

no

yes

par-
tially

par-
tially

par-
tial-
ly

no

Jorm 1994

no

yes

yes

yes

Kathriarachchi

yes

yes

yes

par-
tial-
ly

Law 1995

yes

yes

par-
tial-
ly

par-
tial-
ly

par-
tial-
ly

par-
tial-
ly

par-
tial-
ly

Mackinnon 2003

no

yes

yes

yes

yes

yes

yes

yes

yes

no

no

no

yes

par-
tial-
ly

par-
tially

par-
tially

no

no

yes

yes

yes

no

par-
tial-
ly

yes

yes

no

yes

no

no

no

par-
tially

par-
tially

no

no

no

yes

yes

yes

yes

yes

no

no

no

par-
tial-
ly

yes

yes

yes

yes

no

yes

no

no

un-
clear

un-
clear

un-
clear

par-
tially

par-
tial-
ly

yes

no

yes

par-
tially

yes

no

no

no

yes

par-
tial-
ly

par-
tial-
ly

Morales 1995

yes

yes

yes

yes

yes

yes

yes

yes

yes

yes

yes

no

no

yes

yes

un-
clear

par-
tially

no

no

no

yes

Morales 1997

no

no

yes

yes

yes

yes

yes

yes

yes

yes

yes

yes

no

no

no

par-
tially

no

no

no

no

yes

Senanorong 2001

yes

yes

no

yes

un-
clear

yes

un-
clear

par-
tial-
ly

par-
tial-
ly

yes

yes

yes

no

no

yes

no

par-
tially

no

par-
tial-
ly

no

yes

p
o
p
u
l
a
t
i
o
n
s
(
R
e
v
i
e
w

)

C
o
p
y
r
i
g
h
t

©
2
0
2
1
T
h
e
C
o
c
h
r
a
n
e
C
o

l
l
a
b
o
r
a
t
i
o
n

.

P
u
b

l
i
s
h
e
d
b
y
J
o
h
n
W

i
l
e
y
&
S
o
n
s
,
L
t
d

.

I
n
f
o
r
m
a
n
t
Q
u
e
s
t
i
o
n
n
a
i
r
e
o
n
C
o
g
n
i
t
i
v
e
D
e
c
l
i
n
e
i

n
t
h
e
E
l
d
e
r
l
y
(
I
Q
C
O
D
E
)

f
o
r

t
h
e
d
e
t
e
c
t
i
o
n
o
f
d
e
m
e
n
t
i
a
w

i

i
t
h
n
c
o
m
m
u
n
i
t
y
d
w
e
l
l
i
n
g

7
7

L
i
b
r
a
r
y

C
o
c
h
r
a
n
e

B
e
t
t
e
r
h
e
a
l
t
h
.

T
r
u
s
t
e
d
e
v
i
d
e
n
c
e
.

I
n
f
o
r
m
e
d
d
e
c
i
s
i
o
n
s
.

C
o
c
h
r
a
n
e
D
a
t
a
b
a
s
e
o
f
S
y
s
t
e
m
a
t
i
c
R
e
v
i
e
w
s

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
  (Continued)

Srikanth 2006

yes

yes

yes

yes

yes

yes

yes

yes

yes

yes

no

yes

no

yes

yes

yes

yes

no

yes

no

yes

p
o
p
u
l
a
t
i
o
n
s
(
R
e
v
i
e
w

)

C
o
p
y
r
i
g
h
t

©
2
0
2
1
T
h
e
C
o
c
h
r
a
n
e
C
o

l
l
a
b
o
r
a
t
i
o
n

.

P
u
b

l
i
s
h
e
d
b
y
J
o
h
n
W

i
l
e
y
&
S
o
n
s
,
L
t
d

.

I
n
f
o
r
m
a
n
t
Q
u
e
s
t
i
o
n
n
a
i
r
e
o
n
C
o
g
n
i
t
i
v
e
D
e
c
l
i
n
e
i

n
t
h
e
E
l
d
e
r
l
y
(
I
Q
C
O
D
E
)

f
o
r

t
h
e
d
e
t
e
c
t
i
o
n
o
f
d
e
m
e
n
t
i
a
w

i

i
t
h
n
c
o
m
m
u
n
i
t
y
d
w
e
l
l
i
n
g

7
8

L
i
b
r
a
r
y

C
o
c
h
r
a
n
e

B
e
t
t
e
r
h
e
a
l
t
h
.

T
r
u
s
t
e
d
e
v
i
d
e
n
c
e
.

I
n
f
o
r
m
e
d
d
e
c
i
s
i
o
n
s
.

C
o
c
h
r
a
n
e
D
a
t
a
b
a
s
e
o
f
S
y
s
t
e
m
a
t
i
c
R
e
v
i
e
w
s

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Appendix 10. Heterogeneity in use of IQCODE

Cochrane Database of Systematic Reviews

English

French

Japanese

Sinhalese

Spanish

Thai

17 item

16 item

10 item

3 item

2 item

4 studies

26 item

2 studies

1 study

1 study

1 study

2 studies

1 study

1 study

1 study

1 study

Only 26-item and 16-item IQCODE data were included in the pooled analyses

Some studies used more than one IQCODE

Appendix 11. Commonly used cognitive assessments or screening tools

TEST

Cochrane DTA review in process

Mini-Mental State Examination (MMSE)

GPcog

Minicog

Memory Impairment Screen (MIS)

Abbreviated mental testing

Clock drawing tests (CDT)

Montreal Cognitive Assessment (MoCA)

AD-8 (informant interview)

YES

Still available

Still available

Still available

Still available

Still available

Still available

YES

For each test, the planned review will encompass diagnostic test accuracy in community; primary and secondary care settings.  As well as
standard diagnosis, where applicable reviews will also describe delayed verification design trials.

W H A T ' S   N E W

Date

Event

Description

15 June 2021

Amended

The title and objectives have been changed to make it clear
that screening tests alone cannot give a diagnostic formula-
tion. There have been no other changes. Similar changes have
been made to other Cochrane diagnostic test accuracy reviews

Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the detection of dementia within community dwelling
populations (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

79

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Date

Event

Description

relating to dementia. These changes were made by Cochrane
Dementia and Cognitive Improvement in conjunction with the
Cochrane Mental Health and Neuroscience Network and the re-
view authors, following feedback from a group of dementia re-
searchers, expressing concern that the review titles implied that
short screening tests could make a diagnosis of a dementia sub-
type like Alzheimer’s disease. This interpretation was not in-
tended, but the revised titles and objectives clarify the reviews’
scope. Further details are available at add link to page on web-
site:
https://dementia.cochrane.org/our-reviews/feedback-about-re-
views

15 June 2021

New citation required but conclusions
have not changed

Title and obectives have changed for clarification

H I S T O R Y

Protocol first published: Issue 9, 2012
Review first published: Issue 4, 2014

C O N T R I B U T I O N S   O F   A U T H O R S

ANS assisted with search terms and translation; TJQ and PF drafted the protocol, performed data extraction and quality assessment; CY
assisted with data handling; RMcS and DJS provided support and contributed to manuscript content.

D E C L A R A T I O N S   O F   I N T E R E S T

The review authors have no declarations specific to the review.

S O U R C E S   O F   S U P P O R T

Internal sources

• No sources of support provided

External sources

• RCPSG Travelling Fellowship, UK

Dr Quinn spent a period working directly with the Cochrane Group; this was supported by a RCPSG travelling fellowship.

• Graham Wilson Travelling Scholarship, UK

Dr Quinn's travel and accomodation to allow training in review methodology and analysis was supported by a Graham Wilson Travelling
Scholarship.

D I F F E R E N C E S   B E T W E E N   P R O T O C O L   A N D   R E V I E W

All differences between the protocol and review are described in the main body of the text. A priori we had planned a number of covariate
and sensitivity analyses, however the data set was limited in numbers of studies and studies were too heterogenous to allow all of our
planned analyses. We had originally planned to review the test accuracy of the 16 and 26-item IQCODE separately, however given the
modest number of studies and a comparative analysis suggesting no systematic difference between the two IQCODE formats we used
pooled data for our primary analysis.

I N D E X   T E R M S

Medical Subject Headings (MeSH)

Bias;  Cognitive Dysfunction  [*diagnosis];  Dementia  [*diagnosis];  Health Surveys  [*standards];  *Independent Living;  *Proxy; 
Reproducibility of Results;  Sensitivity and Specificity

Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the detection of dementia within community dwelling
populations (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

80

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

MeSH check words

Aged; Aged, 80 and over; Humans

Cochrane Database of Systematic Reviews

Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the detection of dementia within community dwelling
populations (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

81
